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Summary 
Lipoatrophy in HIV-Infected Children on Antiretroviral Therapy 
Introduction 
Lipoatrophy is a common adverse effect of stavudine and this effect is strongly dose-dependent. 
Stavudine remains the most commonly used paediatric antiretroviral drug in sub-Saharan Africa, yet 
when the current study began in 2009, the prevalence and severity of lipoatrophy in children on 
antiretroviral therapy in sub-Saharan Africa had never been studied. The development of lipoatrophy 
may have serious and far-reaching consequences for patients and their families. The off-label 
stavudine dosing method, prescribed to children whose caregivers do not have access to a 
refrigerator, in which the contents of an adult capsule is mixed into tap water,  has potential for over-
dosing or under-dosing. In addition, children on stavudine continue to be exposed to a 
disproportionately high dose out of line with the reduced adult dose. 
 
Aims 
1. a) To investigate the prevalence and risk factors for lipoatrophy in HIV-infected children in 
Southern Africa 
   b) To identify a simple anthropometric screening tool to detect early lipoatrophy in children 
2. To validate the off-label stavudine dosing method prescribed to children whose caregivers do 
not have access to a refrigerator, with a view to reducing the recommended dose and thereby 
the side-effects. 
 
Methods 
1. a)  We recruited pre-pubertal children on antiretroviral therapy from a family HIV clinic in our 
facility. Lipoatrophy was identified by two experienced paediatric HIV clinicians using a 
standardized grading scale. A dietician performed dietary assessment and anthropometric 
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measurements. Previous antiretroviral exposures were recorded. A subset of recruits received 
Dual-Energy X-ray Absorbtiometry scanning.  
   b) Anthropometric measurements in children with and without lipoatrophy were compared using 
multivariate linear regression adjusting for age and gender. The most discerning 
anthropometric variables underwent Receiver Operating Characteristic curve analysis to 
identify the most appropriate diagnostic cut-off.  
2. a) Accuracy of the standard off-label stavudine dosing method was investigated using high-
performance liquid chromatography to recover active drug from solutions made up using the 
prescribed method. This was compared to the stated drug content of the capsules.  
    b) Bioavailability was investigated by performing a randomized crossover pharmacokinetic study 
wherein healthy HIV-seronegative adult volunteers received one of two generic stavudine 
capsule formulations, either intact or mixed in water using the prescribed method. Plasma 
stavudine concentrations were assayed by liquid chromatography tandem mass spectrometry.  
 
Results 
1. a) Prevalence of lipoatrophy was 36%, and incidence was 12% per person-year. Adjusted odds 
ratio for developing lipoatrophy was 1.9 (CI: 1.3–2.9) for each additional year of accumulated 
exposure to standard-dose stavudine.  
   b) Baseline biceps skin-fold thickness correlated well with maximum lipoatrophy grading score at 
any site, giving a partial correlation coefficient of 0.33 (p=0.0006), and a receiver operating 
characteristic area-under-curve value of 0.75 (CI: 0.64 – 0.84). Biceps skin-fold thickness 
<5mm at baseline had a sensitivity of 89% (CI: 67–100%) and a negative predictive value of 
97% (CI: 91–100%) for predicting which children would go on to develop lipoatrophy by 15 
month follow-up. Specificity was 60% (CI: 46–75%) and positive predictive value was 32% (CI: 
14–50%). 
Stellenbosch University http://scholar.sun.ac.za
5 
 
2. a) Recovery of active drug from solution was 97.1%, 97.4% and 93.8% for the proprietary and two 
generic formulations respectively.  
    b) Pharmacokinetic parameters of the off-label dosing method were well within the target range 
of intact capsule dosing for both generics. 
 
Conclusions 
1. a) The prevalence and incidence of lipoatrophy in pre-pubertal children on antiretroviral therapy 
in South Africa is high. Cumulative exposure to standard-dose stavudine was the greatest risk 
factor for lipoatrophy.  
   b) Biceps skin-fold thickness provided reasonable sensitivity and specificity to detect and predict 
lipoatrophy in pre-pubertal children on antiretroviral therapy. 
2. The off-label dosing method for stavudine prescribed to children whose caregivers do not have 
access to a refrigerator is reasonably accurate and is bioequivalent to intact capsule 
administration.  
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Opsomming 
Lipoatrofie in MIV-geïnfekteerde kinders op antiretrovirale terapie 
Inleiding 
Lipoatrofie is 'n algemene nadelige uitwerking van stavudien en hierdie effek is sterk dosis-
afhanklike. Stavudien bly die mees algemeen gebruikte paediatriese antiretrovirale medikasie in sub-
Sahara Afrika, maar toe ons studie begin het, was lipoatrofie in kinders op antiretrovirale terapie in 
sub-Sahara Afrika nog nooit voorheen bestudeer nie. Die ontwikkeling van lipoatrofie kan ernstige en 
verreikende gevolge vir die pasiënt en hul familie hê. Die af-etiket stavudien dosering metode 
voorgeskryf aan kinders wie se versorgers nie toegang tot 'n yskas het nie het 'n aansienlike potensiäal 
vir oor-dosering of onder-dosering. Daarbenewens, is kinders op stavudien blootgestel aan 'n 
disproporsionele hoë dosis uit-pas met die verminderde volwasse dosis. 
 
Doelwitte 
1. a) Om ondersoek in te stel na die voorkoms en risiko faktore vir lipoatrofie in MIV-geïnfekteerde 
kinders in Suid Afrika 
   b) Om 'n eenvoudige antropometriese instrument te identifiseer om vroeë lipoatrofie op te spoor in 
kinders op antiretrovirale medikasie 
2. Om die af-etiket stavudien dosering metode wat voorgeskryf is aan kinders wie se versorgers nie 
toegang tot 'n yskas het nie te valideer, met 'n oog op die vermindering van die aanbevole dosis 
 
Metodes 
1. a) Ons het 'n groep van onder-puberteitsjarige kinders op antiretrovirale terapie gewerf uit 'n 
familie MIV kliniek in ons fasiliteit. Lipoatrofie is geïdentifiseer deur twee ervare MIV pediaters deur 
gebruik van 'n gestandaardiseerde gradering skaal. 'n Diëetkundige het diëet assessering en 
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antropometriese metings uitgevoer. Vorige antiretrovirale blootstellings is aangeteken. In 'n subset 
was Dual-energie X-straal Absorbtiometry (DXA) skandering uitgevoer. 
   b) Antropometriese metings in kinders met en sonder lipoatrofie is vergelyk met behulp van 
meerveranderlike lineêre regressie aangepas vir ouderdom en geslag. Die mees kieskeurige 
antropometriese veranderlikes het Receiver Operating Curve analise ondergaan om die mees geskikte 
diagnostiese afgesnypunt te identifiseer. 
2. a) Akkuraatheid is ondersoek deur gebruik te maak van hoë werkverrigting vloeistofchromatografie 
om aktiewe medikasie vanuit oplossings te herstel, wat gemeng is soos aangedui deur die 
voorgeskrewe af-etiket dosering metode. 
    b) Biobeskikbaarheid is ondersoek deur die uitvoering van 'n ewekansige oorgesteekde 
farmakokinetiese studie waarin gesonde MIV- negatiewe volwasse vrywilligers een van twee generiese 
stavudien kapsule formulerings ontvang het, óf heel of in water gemeng soos aangedui deur die 
voorgeskrewe af-etiket dosering metode. Plasma stavudien konsentrasies is gemeet deur 
vloeistofchromatografie tandem massaspektrometrie. 
 
Uitslae   
1. a) Voorkoms van lipoatrofie was 36%, en insidensie was 12% per persoon-jaar. Aangepaste Odds 
ratio vir die ontwikkeling van lipoatrofie was 1,9 (CI: 1,3-2,9) vir elke addisionele jaar van opgehoopte 
blootstelling aan standaard dosis stavudien. 
   b) Biceps vel-vou dikte <5mm het 'n sensitiwiteit van 89% (CI: 83-96%) en 'n negatiewe 
voorspellende waarde van 90% (CI: 84-96%) vir die opsporing en voorspelling van lipoatrofie. 
2. a) Herwinning van aktiewe medikasie uit oplossings was 97,1%, 97,4% en 93,8% vir die 
oorspronklike en twee generiese formulerings onderskeidelik. 
    b) Farmakokinetiese parameters van die af-etiket dosering metode was wel binne die teikenband 
van ongeskonde kapsule dosering vir beide generiese formulerings. 
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Gevolgtrekkings 
1. a) Die voorkoms van lipoatrofie in onder-puberteitsjarige kinders op antiretrovirale terapie in Suid-
Afrika is hoog. Die bedrag stavudien waaraan kinders blootgestel is moet hersien word. Die standaard 
stavudien dosis vir kinders moet herge-evalueer word. 
   b) Biceps vel-vou dikte het redelike goeie sensitiwiteit en spesifisiteit om lipoatrofie op te spoor en 
te voorspel. 
2. Die af-etiket dosering metode vir stavudien voorgeskryf aan kinders wie se versorgers nie toegang 
tot 'n yskas het nie is redelik akkuraat en is bio-ekwivalent aan ongeskonde kapsule administrasie. 
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Literature Review 
Lipoatrophy in HIV-Infected Children on Antiretroviral Therapy 
Antiretroviral agents have led to dramatic advancements in life expectancy and quality of life for 
people living with HIV/AIDS. As a result, the focus of therapeutic management and research has 
shifted to delayed adverse drug effects and chronic diseases (1). Lipoatrophy is a common adverse 
effect of stavudine and this effect is strongly dose-dependent (2). Lipoatrophy was previously believed 
to be uncommon in children, and as a result, very little attention has been given to surveillance, 
diagnosis and risk factor alteration in children, particularly pre-pubertal children (3). However, 
European studies have found a progressively increasing prevalence of lipoatrophy in children on 
antiretroviral therapy (ART), affecting up to 28% in the most recent studies (4). Lipoatrophy has 
become one of the most common adverse drug effects in children on antiretroviral therapy (ART) (5). 
When the current study began in 2009, the prevalence and risk factors for lipoatrophy in children 
living in sub-Saharan Africa had not previously been studied despite the fact that over 90% of the 3.4 
million HIV-infected children worldwide live in sub-Saharan Africa (6). Some data was presented by 
the NEVEREST study group at the 2011 International AIDS Society Conference, which showed 
consistently greater subcutaneous fat in children on protease inhibitors compared to those on non-
nucleoside reverse transcriptase inhibitors, and generally low subcutaneous fat in children on 
stavudine (7). They did not define a diagnostic cut-off for lipoatrophy and thus no prevalence figures 
were given. 
 
The development of lipoatrophy may have serious and far-reaching consequences for the patient and 
their families. Lipoatrophy looks very similar to AIDS wasting syndrome, known as “Slims disease” 
throughout Africa, and may result in the same stigmatization (8). In contrast to the developed world, 
stigmatization due to HIV in sub-Saharan Africa may lead to loss of housing, loss of employment or 
livelihood, denial of schooling, denial of healthcare, secondary stigmatization of family members and 
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physical violence (9-10). Fear of developing lipoatrophy may cause caregivers to become non-
adherent with ART, leading to loss of CD4 cells, subsequent opportunistic infection and possibly 
death (11). In multivariate logistic regression modelling, fat distribution abnormalities were an 
independent risk factor for subsequent non-adherence (11).  Reports of partial recovery of lipoatrophy 
are limited to the least severely affected individuals (12). Severe lipoatrophy may not be reversible 
(13-14). This is understandable since the mechanism of lipoatrophy involves progressive apoptosis of 
adipocytes, which do not recover (15), as opposed to nutritional wasting where adipocyte fat stores 
shrink but the cell survives. However, stigmatization may only occur when lipoatrophy is severe 
enough to be easily recognizable by the broader community. Stigmatization can be prevented if 
lipoatrophy is diagnosed early and ART is switched to arrest lipoatrophy progression (14). 
Communities with the highest prevalence of HIV are the most likely to recognize HIV-related or ART-
related body changes. Southern Africa has the highest HIV prevalence in the world (6). 
 
While lipoatrophy has been well described in Europe and the United States of America, there is 
almost no data on this syndrome in pre-pubertal children in sub-Saharan Africa, despite the fact that 
over 90% of the 3.4 million HIV-infected children worldwide live there (6). In South Africa alone, 
more than a million children under 15 years of age are HIV-infected, and, despite reductions in 
vertical transmission, an additional 59,000 new infections in children are added each year (16). South 
Africa has the largest antiretroviral treatment program in the world, with an estimated 163,000 
infants and children on ART by August 2012, and many more added each year (personal 
communication – South African National Department of Health). The severity and extent of 
lipoatrophy in pre-pubertal children living in sub-Saharan Africa is unknown (5). 
 
As there is evidence of genetic and ethnic determinants in lipoatrophy (17), it is important to study 
lipoatrophy specifically in sub-Saharan African populations. Four earlier studies from the developed 
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world have included immigrant children from sub-Saharan Africa living in Paris (18), London (19), 
Brussels (20) and a combination of sites in Western Europe (21), and found a lipoatrophy prevalence 
of 11%, 8%, 20% and 17% respectively. However, many differences exist between immigrant African 
populations living in the developed world and populations who remain in Africa, and findings may 
not be generalizable. Specifically, obesity is more common in Europe (22), which may mask early 
lipoatrophy, whereas under-nutrition is common in sub-Saharan Africa. In addition, stavudine is the 
most widely used first-line antiretroviral agent for children in the developing world, particularly sub-
Saharan Africa, where 49% of children on ART are on a stavudine-based regimen (23). Thus, 
lipoatrophy in children in sub-Saharan Africa needed to be studied directly. 
 
The prevalence of lipoatrophy in children on ART in Europe appears to be rising over time: Studies 
from 2005 and 2006 estimated the prevalence of lipoatrophy at 8% to 11% (18-19) whereas the most 
recent studies have found a prevalence of around 28% (4). Accumulation of cases is not surprising 
since lipoatrophy changes may persist despite switching of ART regimen (13-14), and survival rates 
are high in medication-adherent children, who are at highest risk of lipoatrophy. 
 
Mechanism 
The mechanism of lipoatrophy is related to (NRTI)-induced mitochondrial damage, particularly in 
adipocytes (24), which may result in apoptosis. NRTIs such as stavudine can damage adipocyte 
mitochondria (24) and cause a reduction in functioning mitochondria in adults (25). Other chronic 
toxic effects such as lactic acidosis and peripheral neuropathy have also been associated with 
mitochondrial dysfunction (26-27) but are uncommon in children (28-29). It has been suggested that 
unknown agents released from damaged mitochondria in adipocytes may directly trigger apoptosis, 
which leads to subcutaneous fat loss. Decline of mitochondrial DNA in peripheral leucocytes may 
provide an early warning sign of impending lipoatrophy in patients exposed to antiretrovirals (30-31).  
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In addition, circulating growth hormone levels are significantly reduced in patients with lipoatrophy, 
and this may contribute to the reduction in sub-cutaneous adipose tissue (32). 
 
Risk Factors 
Lipoatrophy does not occur in all children exposed to ART (4, 21, 33). Some show no signs of fat 
changes despite many years of stavudine or zidovudine exposure, whereas others develop lipoatrophy 
within 18 months of starting ART (33). This variation may be due to genetic differences that increase 
or decrease an individual’s susceptibility to lipoatrophy (17, 34-35). Particular mitochondrial DNA 
sub-groups (haplogroups) have been associated with a vulnerability to developing lipoatrophy after 
exposure to ART (36). A recent study showed that Caucasian American men on ART who have the H 
mitochondrial haplogroup were at significantly increased risk of lipoatrophy (36). A plausible 
explanation may be that variations of mitochondrial DNA in adipocytes may reduce the efficiency of 
energy production or lead to increased oxygen free-radical production, resulting in a reduced 
mitochondrial functional reserve and an increased vulnerability to apoptosis when exposed to 
mitochondrial toxins such as antiretrovirals.  
 
Lipoatrophy has been clearly linked to the NRTI drugs stavudine, zidovudine and didanosine (20, 37-
41), and the risk appears to be proportional to the dose (42). In comparison, the NRTI drugs abacavir, 
tenofovir, and lamivudine have minimal or no lipoatrophy-causing effect (43). The non-nucleoside 
reverse transcriptase inhibitor efavirenz is a less potent cause of lipoatrophy (20). In addition, 
efavirenz has been associated with lipomastia in some children, although this usually resolves 
spontaneously without withdrawal of efavirenz (44-45). Protease inhibitors have been linked to 
dyslipidaemia (46), but have not been convincingly implicated in lipoatrophy. In fact, protease 
inhibitors have been associated with global increases in fat deposits (47). 
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The risk of lipoatrophy in patients on stavudine is strongly dependent on the dose. In 2007, an 
influential review of the previous 15 years’ data by Hill et al (42) showed that a lower stavudine dose 
of 20 or 30mg twice daily results in a markedly lower risk of lipoatrophy, while maintaining excellent 
antiviral efficacy (48-49). This led the World Health Organization to recommend a reduction in the 
usual dose of stavudine for adults weighing over 60 kg from 40 mg to 30 mg twice daily (50). The 
current standard paediatric dose of stavudine (1 mg/kg/dose twice daily) was determined by direct 
extrapolation from the pharmacokinetic parameters of the adult dose of 40 mg twice daily, using data 
from a few small but well-controlled paediatric pharmacokinetic studies (51-53) which showed that 
an oral dose of 1 mg/kg/dose twice daily in children under 12 years results in plasma exposure similar 
to that of adults taking 40 mg twice daily, and that an oral dose of 0.5 mg/kg/dose twice daily in 
children results in plasma exposure similar to that of adults taking 20 mg twice daily.  The WHO 
recommended dose of stavudine for children, however, has not yet been reduced. Consequently 
children on stavudine continue to be exposed to a disproportionately high dose, which may result in 
more rapid accumulation of metabolic adverse effects than adults on the reduced dose. 
 
Stavudine 
Stavudine is now rarely used in the developed world. The 2010 World Health Organization 
antiretroviral guidelines advise that stavudine should be phased out where possible (54). However, 
stavudine remains within the nationally recommended paediatric first-line ART guidelines for 
numerous developing countries. In South Africa, stavudine was the first choice nucleoside reverse 
transcriptase inhibitor for children, together with lamivudine, from the beginning of the ART access 
program in 2004 until 2010, when it was replaced with abacavir. Current South African guidelines 
state that children taking stavudine should continue unless side-effects develop. Thus the majority of 
children treated for HIV in South Africa remain on stavudine. In most other sub-Saharan African 
countries the cost of abacavir remains prohibitive and stavudine remains the most commonly used 
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paediatric antiretroviral there, with around 49% of children on ART on a stavudine-based regimen 
(23, 55).  
 
Paediatric stavudine solution (Zerit® - Bristol Myer Squibb, Uxbridge, United Kingdom), available as 
a dry powder, must be reconstituted with a specific volume (202ml) of distilled water. Once 
reconstituted, the solution must be transported by the caregiver in a cooler box, requires refrigeration 
at 4oC, and is then only stable for one month (56). Paediatric liquid formulations present significant 
logistical difficulties in rural or resource-constrained settings. Refrigeration is often not possible in 
rural or resource-limited areas. Where fixed drug combinations are not available, logistical barriers to 
the use of the paediatric stavudine formulation in resource-limited areas have forced paediatric 
clinicians to prescribe an off-label dosing method that makes use of adult stavudine capsules in lieu of 
the liquid paediatric formulation. The adult capsule formulation is stable at room temperature 
(<25oC) for two years (57). The South African Department of Health guidelines (58) advise that 
caregivers should be instructed to disperse the contents of an adult capsule in 5ml water and then 
withdraw the required fraction of the mixture using a syringe. The contents of Stavudine capsules do 
not dissolve completely, and rapidly form a sediment at the bottom of the container. The caregiver is 
advised to re-agitate the mixture carefully in order to re-suspend the sediment that collects at the 
bottom of the container, before drawing up the aliquot for the child. This administration method has 
been termed the “opened capsule” dosing method. Manufacturers do not recommend that capsules be 
opened or suspended in water before consumption (56). As there were no published data on the 
accuracy or bioavailability of the “opened capsule” dosing method, the potential for over- or under-
dosing may be significant. In addition, the South African National Department of Health have 
prescribed that the volume of mixture that corresponded to the usual dose (1mg/kg twice daily) 
should be rounded up to the nearest practical volume of mixture, usually 2.5ml, which could result in 
doses as high as 1.4mg/kg. 
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Fixed drug combination effervescent tablets incorporating stavudine have been introduced in certain 
central African countries (Uganda, Zambia, Malawi). These are marketed as Triomune Adult®, 
Triomune Junior® and Triomune Baby®. These formulations were produced by Cipla Life Sciences 
(Mumbai, India) as part of a social responsibility response to the dearth of paediatric antiretroviral 
formulations suitable for sub-Saharan African conditions. Triomune Junior® and Baby® remain 
unregistered in Southern Africa countries (South Africa, Zimbabwe, Mozambique), although they 
have been registered in Botswana and Namibia (Personal communication – Cipla Medpro). 
  
The most common alternative to stavudine is zidovudine, with around 47% of children on ART on a 
zidovudine-based regimen (23, 59), Zidovudine also causes lipoatrophy albeit less severely (60). In 
addition, the danger of zidovudine-related bone marrow suppression, a common problem with 
varying degrees of severity, is significant and requires some laboratory monitoring (59, 61). 
Laboratory facilities are not always reliably available in resource-limited settings. Abacavir is the 
current preferred first line drug in paediatric care in the developed world (54). However, the cost of 
abacavir is prohibitive for most resource-limited healthcare budgets in sub-Saharan Africa (62). All 
antiretroviral drugs carry risks of adverse effects that must be balanced against clinical benefit, 
particularly in primary healthcare settings in sub-Saharan Africa where surveillance for adverse 
effects may be limited. Stavudine offers an almost toxicity-free safety profile in the first 6 to 12 
months of use (2), with potent antiviral efficacy (42). For unknown reasons, thymidine-related 
peripheral neuropathy and symptomatic lactic acidosis are rare in pre-pubertal children, with only 
isolated reports in published literature (28-29, 63-65). 
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Diagnosis 
An objective case definition for lipoatrophy has been established for adults, which incorporates 
computed tomography (CT) measurements, Dual Energy X-ray Absorptiometry (DXA), and blood 
lipid and electrolyte values (66). However, this case definition has not been validated in children. 
Serial DXA is sometimes used in developed countries to monitor fat volume and distribution in 
children on potentially lipoatrophy-inducing ART. The most robust method of diagnosing lipoatrophy 
in children is the skilled visual assessment of subcutaneous limb and face fat performed by 
experienced paediatric HIV clinicians who have been specifically trained to do this (21). In clinical 
practice, however, the diagnosis is most commonly made by a non-specialist clinician who has been 
trained to recognise the typical features. Physical signs in children are due to loss of subcutaneous fat 
in limbs, buttocks and face, with or without accumulation of intra-abdominal visceral fat (20, 39-41). 
At least 30% of peripheral fat must be lost before lipoatrophy becomes visibly evident (67). Fat loss is 
slowly progressive and often goes unnoticed until it is severe. Early facial fat loss may be subtle and 
difficult to detect. In the absence of lipoatrophy, facial muscles are covered in fat and are not 
normally noticeable. Loss of facial fat results in a lean, muscular appearance of the face with sunken 
cheeks and deep laugh-lines when smiling. Loss of limb fat results in reduced skin-fold thickness 
(SFT), prominent limb veins and a well-defined, muscular appearance of limbs in the presence of a 
normal or enlarged abdomen. A torso-to-arm SFT ratio above 2, calculated as (subscapular SFT + 
suprailiac SFT) / (biceps SFT + triceps SFT), has been used as a diagnostic criterion in a previous 
study (68), however, the number of children with lipoatrophy in that study was small (n=4) and were 
all pubertal, and data was presented as median z-scores without inter-quartile ranges. Loss of buttock 
fat, with or without enlargement of the abdomen, may result in an increased waist-to-hip ratio 
(WHR). Breast enlargement and “buffalo hump” (accumulation of fat in the nape of the neck) may 
occur after puberty (69). Diagnosis of early lipoatrophy in children remains difficult. CT and DXA are 
often not feasible in sub-Saharan Africa, and paediatric-trained HIV specialists are scarce. 
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Management 
Since the disfigurement caused by lipoatrophy may be permanent, the focus of management is on 
early detection and arresting progression. Once identified, the most likely offending antiretroviral 
drug is usually withdrawn and is replaced by a less lipoatrophy-inducing antiretroviral. When 
lipoatrophy is diagnosed, significant benefit in halting progression has been shown by switching from 
the thymidine NRTI antiretroviral drug to a non-thymidine NRTI such as abacavir (43). Where 
abacavir is not available, stavudine may be switched to zidovudine with moderate results (12). 
Tenofovir is generally avoided in children because of its renal and bone toxicity, which are believed to 
be significantly more common and more pronounced in children than adults (70-72). However, there 
may be a place for switching to tenofovir in adolescents (73). Switching to an alternative antiretroviral 
agent typically arrests progression of lipoatrophy, and may result in a small degree of reversal if 
lipoatrophy is caught early (14). Various authors have demonstrated that the more advanced the 
lipoatrophy, the less likely it is to reverse when the offending drug is removed (74-75). Intradermal 
injections of a biodegradable filler such as poly-L-lactic acid (Sculptura®) can ameliorate the aesthetic 
effect of facial lipoatrophy in adults (76). However the pain and discomfort of this treatment make it 
inappropriate for children. In addition, the cost is significant and the effect is not permanent and 
injections may need to be repeated. Uridine (NucleomaxX®) partially reverses the mitochondrial 
toxicity caused by thymidine NRTIs, and may have a small but beneficial effect on disfiguring 
lipoatrophy (77). However, uridine is not currently available in South Africa. Growth hormone-
releasing hormone analogues may be helpful in the treatment of lipoatrophy (78). The mechanism 
probably involves reversing the reduced growth hormone levels that are consistently found in 
patients with lipoatrophy. Although the side-effect profile of growth hormone-releasing hormone 
therapy is attractive, the cost is prohibitive. Future treatments may involve adipokines such as leptin, 
but these remain experimental (38).   
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Gaps in current knowledge 
1. The severity and extent of lipoatrophy in pre-pubertal children living in sub-Saharan Africa 
was unknown (5).  
2. Since stavudine is the most common cause of lipoatrophy and the effect is strongly dose-
related, it is important to establish the accuracy and bioavailability of the off-label stavudine 
dosing method prescribed to children whose caregivers do not have access to a refrigerator, 
with a view to reducing the recommended dose. In addition, as a number of generic 
alternatives are available and regional purchasing mechanisms may favour switching 
suppliers, the various generic capsule preparations needed to be studied in order to determine 
which preparations, if any, are suitable for the off-label “opened capsule” dosing method.  
 
Thus the aims of this PhD were two-fold: 
1. To investigate the prevalence and risk factors for lipoatrophy in HIV-infected children on ART 
in Southern Africa.  
2. To investigate the accuracy and bioavailability of the off-label stavudine dosing method 
prescribed to children whose caregivers do not have access to a refrigerator, with a view to 
reducing the recommended dose. 
These aims have been fulfilled, and are described in chapters 1 to 5. The respective published 
manuscripts have been added as appendices. Serendipitously during the course of these studies, I 
realized that a combination of anthropometric measurements might render reasonable sensitivity and 
specificity to act as a simple screening tool to detect lipoatrophy at an early stage in areas where 
specialized diagnostic skills and equipment are scarce. This would allow earlier antiretroviral drug 
switches to be made to arrest the progression of lipoatrophy and prevent potentially stigmatizing face 
and limb disfigurement. The study that describes that screening tool is presented in chapters 2 and 3 
and the published manuscript has been added as an appendix.   
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Chapter 1 
Prevalence and risk factors for lipoatrophy in pre-pubertal South African 
children on antiretroviral therapy 
Abstract 
Background: Despite changes in WHO guidelines, stavudine is still used extensively for treatment of 
paediatric HIV in the developing world. Lipoatrophy in sub-Saharan African children can be 
stigmatizing and have far-reaching consequences. The severity and extent of lipoatrophy in pre-
pubertal children living in sub-Saharan Africa was unknown. 
Methods: In this study, children who were 3-12years old, on antiretroviral therapy and pre-pubertal 
were recruited from a Family HIV Clinic in South Africa. Lipoatrophy was identified and graded by 
consensus between two experienced HIV paediatricians using a standardized grading scale. A 
professional dietician performed dietary assessments and anthropometric measurements of trunk 
and limb fat. Previous antiretroviral exposures were recorded. In a Dual-Energy X-ray 
Absorbtiometry (DXA) substudy, 42 subjects were scanned. Lipoatrophy assessment was repeated at 
least one year later. 
Results: Among 100 recruits, the prevalence of visually obvious lipoatrophy was 36% (95% CI: 27%–
45%). Annual incidence of lipoatrophy was 12% (CI: 5-20%) per person-year of follow-up. 
Anthropometry and DXA measurements corroborated the clinical diagnosis of lipoatrophy:  Both 
confirmed significant, substantial extremity fat loss in children with visually obvious lipoatrophy, 
when adjusted for age and sex. Adjusted odds ratio for developing lipoatrophy was 1.9 (CI: 1.3 - 2.9) 
for each additional year of accumulated exposure to standard-dose stavudine.  Cumulative time on 
standard-dose stavudine was significantly associated with reductions in biceps and triceps skin-fold 
thickness (p=0.008). 
Conclusions: The prevalence of visually obvious lipoatrophy in pre-pubertal South African children 
on antiretroviral therapy is high. The amount of stavudine that children are exposed to needs review. 
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Resources are needed to enable low- and middle-income countries to provide suitable paediatric-
formulated alternatives to stavudine-based paediatric regimens. The standard stavudine dose for 
children may need to be re-evaluated.  Diagnosis of lipoatrophy at an early stage is important to avoid 
stigmatization. Diagnosis using visual grading requires training and experience, and DXA and 
comprehensive anthropometry are not commonly available. A simple objective screening tool is 
needed that can identify early lipoatrophy in resource-limited settings where specialized skills and 
equipment are not available.   
 
Aim 
We explored the prevalence and risk factors for lipoatrophy in a group of pre-pubertal South African 
children on ART. We also correlated the visual diagnosis of lipoatrophy with objective 
anthropometric measurements of body fat in the whole group, and with Dual Energy X-ray 
Absorptiometry (DXA) findings in a subgroup.  
 
Methods 
The Family Clinic for HIV at Tygerberg Children’s Hospital is a public-sector clinic providing ART to 
infants and children from the Northern suburbs of Cape Town. In this study, children who were 3-12 
years old, on antiretroviral therapy and pre-pubertal were recruited between February 2010 and 
January 2011. Pre-pubertal status was defined as Tanner stage 1 for genital and pubic hair 
development in boys, and Tanner stage 1 for pubic hair development with Tanner stage 1 or 2 for 
breast development in girls. Using a review of our electronic health record database, we identified 190 
subjects that potentially met the inclusion criteria. Of these, 124 attended clinic during the study 
period and could be approached for screening. A total of 121 provisionally agreed to participate, but 
21 did not attend the study visit nor did they respond to attempts at further contact. One hundred 
subjects were finally recruited.  There was no difference in demographic characteristics of the 100 
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enrolled subjects and the 90 who were not recruited (p>0.20 for age, gender, cumulative time on 
standard-dose stavudine and CD4).  
 
Lipoatrophy was identified and graded by consensus between two HIV paediatricians who were 
experienced in identifying lipoatrophy, using the following lipoatrophy grading scale defined by 
existing literature (33, 66, 68): 0 – No fat changes; 1 – Possible minor changes, noticeable only on 
close inspection; 2 – Moderate changes, readily noticeable to an experienced clinician or a close 
relative who knows the child well; 3 –  Major changes, readily noticeable to a casual observer. Face, 
arms, legs and buttocks were assessed for loss of subcutaneous fat resulting in abnormally prominent 
limb veins, a lean, muscular appearance of limbs and face, and loss of gluteal fat pad with reduction 
in buttock size and loss of gluteal contour. Where the assessment of the two investigators did not 
concur, the change was graded as 1. Lipoatrophy was defined as a score of 2 or 3. The parents’ 
subjective assessments of fat changes were recorded. 
 
Durations of previous antiretroviral exposures and demographics were recorded from our electronic 
health record database. HIV RNA and CD4 values were extracted from our central electronic 
laboratory results server. Doses of antiretroviral drugs followed nationally prescribed protocols. For 
stavudine this meant a minimum of 1mg/kg twice daily rounded up to the nearest practical dose. A 
professional dietician performed dietary assessments and anthropometric measurements of body 
mass, trunk and limb fat using a non-stretchable tape-measure (model number F10-02DM, Muratec 
KDS Corporation, Kyoto, Japan), a high-precision Harpenden® skin-fold caliper (Baty International, 
West Sussex, United Kingdom), a ShorrBoard® stadiometer (Shorr Productions, Maryland, USA), 
and a precision weighing scale (model number UC-321, A&D Company, Tokyo, Japan) which was 
calibrated daily. Measurements included mid-upper arm circumference, mid-thigh circumference, 
chest circumference, waist circumference, hip circumference, biceps skin fold thickness (SFT), triceps 
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SFT, iliac crest SFT, sub-scapular SFT, mid-thigh SFT, height and weight. The following ratios were 
derived: waist to hip circumference ratio; body mass index; torso to arm SFT ratio ([subscapular + 
iliac crest SFT] / [biceps + triceps SFT]). Lipoatrophy assessment was repeated at least one year later. 
 
In a DXA substudy, DXA scans were performed using a Hologic Discovery (Bedford, Massachusetts, 
USA) to objectively confirm lipoatrophy. Trunk and limb fat mass, lean mass and fat percentage were 
measured.  
 
Since very little is known about the normal paediatric population in South Africa, additional 
normative data was collected from healthy age- gender- and socioeconomically-matched HIV-
uninfected children from the same community who had been enrolled as part of a different study at 
our research unit (79). We gathered anthropometry and DXA data from 57 children in order to 
supplement what is known from published population norms for age-related anthropometric and 
DXA variables, which are currently only derived from developed country paediatric populations. This 
local normative data appears in tables 2 and 3 to assist the reader to gauge the magnitude of the 
changes found in lipoatrophy-affected children. 
 
In univariate analyses, a t-test was used for parametric data, Wilcoxon rank sum test was used for 
non-parametric data, and Fisher’s exact test was used for categorical data. Non-parametric 
continuous data are quoted as median (interquartile range), and parametric continuous data are 
quoted as mean (standard deviation) or mean (95% confidence interval) where appropriate. Multiple 
logistic regression was used to study the risk factors associated with visually obvious lipoatrophy, 
adjusting for age and CD4. Multiple linear regression models were used to compare fat distributions 
captured by anthropometry and DXA between children with and without lipoatrophy, adjusting for 
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age and sex. A least squares approach was used for multivariable modelling. All statistical analyses 
were performed using R version 2.10.0 (Bell Laboratories, New Jersey).   
 
This study was designed in accordance with the guidelines of the International Conference on 
Harmonization for Good Clinical Practice and with the Declaration of Helsinki (version 2000), and 
approved and monitored by the Ethics Committee for Human Research of the Stellenbosch 
University, approval reference number N08/11/349. Written informed consent was obtained from 
each caregiver prior to participation, and informed assent was obtained from capable children. All 
patient-related data were stored in a password-secured database under a patient identifying number 
and kept strictly confidential. The choice of sample population satisfies the ethical principle of justice 
as this study will directly benefit the community from which the data is drawn by leading to 
recommendations about best practice in public-sector HIV clinics in South Africa.  
 
Results 
One hundred subjects were recruited. The prevalence of visually obvious lipoatrophy was 36% (95% 
CI: 27% to 45%). One of the 15 girls with lipoatrophy and 2 of the 33 girls without lipoatrophy were 
Tanner stage 2 for breast development at recruitment. All others were Tanner stage 1. Overall, 
children with and without lipoatrophy had similar body mass index, weight-for-age Z-score, height-
for-age Z-score, gender distribution, ethnic distribution, WHO clinical stage, viral load and mean 
CD4 (see table 1). In children with lipoatrophy, face changes were graded as more severe than limb 
changes in 11/36; the same as limb changes in 24/36; and less severe than limb changes in 1/36. In all 
cases, lipoatrophy changes were deemed symmetrical. Twelve of the 36 cases had severe changes 
(grade 3) similar to the child represented in figures 1 and 2. The parents’ subjective assessments 
tended to underestimate the presence and severity of subcutaneous fat changes. In no recruits did the 
parent assess the changes as more severe than the clinicians’ consensus assessment. 
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On formal dietary assessment, 11 children without lipoatrophy (18%) versus 5 children with 
lipoatrophy (15%) had an inappropriate diet:  6 (10%) versus 5 (15%) were over-consuming refined 
carbohydrates; 1 (2%) versus 0 (0%) had inadequate carbohydrate consumption; 3 (5%) versus 1 (3%) 
were over-consuming fat; 2 (3%) versus 0 (0%)  had inadequate fat consumption; 4 (6%) versus 0 
(0%) had inadequate total daily calorie consumption. Dietary data was missing in 2 children from 
each group. 
 
Table 1 reflects that, on univariate analysis, overall time on ART, time on standard-dose stavudine, 
cumulative lamivudine exposure, cumulative efavirenz exposure, and greater age were associated 
with visually obvious lipoatrophy. Zidovudine and didanosine were not included in the analysis as too 
few children had been exposed to these drugs (33 and 6 children respectively, with p=0.56 and 0.58 
respectively). WHO clinical stage did not correlate with the presence or absence of lipoatrophy 
(p=0.78). A multivariate logistic regression model controlling for age and CD4%, incorporating all 
antiretroviral exposures found significant in the univariate analysis, identified cumulative time on 
standard-dose stavudine as the predominant risk factor independently associated with lipoatrophy 
(adjusted odds ratio = 1.9 for each additional year of accumulated exposure to standard-dose 
stavudine; 95% CI: 1.3 to 2.9; p=0.002), while efavirenz and lamivudine were no longer associated. 
Abacavir exposure was not included in the multivariate model as it was only used for children who 
had developed a complication of stavudine therapy. Cumulative time on standard-dose stavudine was 
significantly associated with reductions in biceps and triceps SFT (p=0.008). Thirty-five of the 36 
children with lipoatrophy and 53 of the 64 children without lipoatrophy had ever been exposed to 
stavudine, and 51/64 (80%) of children without lipoatrophy were on stavudine-based regimens at 
recruitment. Table 1 shows the comparative antiretroviral exposures and data from the univariate and 
multivariate analysis. All but one of the children with lipoatrophy had been exposed to more than 18 
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months of stavudine therapy. At the time of recruitment, 23/36 children with lipoatrophy had been 
off stavudine for at least six months with only minimal or mild resolution of their fat abnormalities. 
 
Adjusting for age and sex, anthropometrics confirmed significant, substantial extremity fat loss in 
children with visually obvious lipoatrophy (see table 2). There were no statistically significant 
differences in anthropometric measurements of fat amount and distribution between children 
without lipoatrophy and the local HIV-uninfected paediatric population. Biceps SFT, triceps SFT, 
torso-to-arm SFT ratio and waist-to-hip circumference ratio correlated with maximum lipoatrophy 
grading score, giving regression coefficients of 0.34 (0.17 to 0.65, p=0.002), 0.31 (0.17 to 0.59, 
p=0.0006), 3.36 (1.57 to 7.16, p=0.002) and 4.23 (0.37 to 8.10, p=0.03) respectively when adjusted 
for age and sex.  
 
In the DXA substudy, there was no difference in gender, cumulative time on standard-dose stavudine 
or CD4 between the 42 subjects who underwent DXA scanning and the 58 who did not (p>0.50 for 
all). The children who underwent DXA were marginally younger than those who did not (7.1 versus 
8.0 years, p=0.03). Measures of fat amount and distribution confirmed significant, substantial 
extremity fat loss in children with visually obvious lipoatrophy, when adjusted for age and sex (see 
table 3). There were no statistically significant differences in DXA measures of fat amount and 
distribution between children without lipoatrophy and the local HIV-uninfected paediatric 
population. Limb fat versus limb lean ratio, limb fat versus total body weight ratio, limb fat versus 
body mass index ratio and total limb fat (converted to grams) correlated with maximum lipoatrophy 
grading score, giving regression coefficients of -2.24 (-0.86 to -3.62, p=0.003), -0.02 (-0.01 to -0.03, 
p=0.002), -0.015 (-0.006 to -0.024, p=0.003) and -0.8 (-0. 3 to -1.4 grams, p=0.006) respectively 
when adjusted for age and sex. 
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Lipoatrophy grading scores at baseline and at follow-up are presented in table 4 and figure 3. Follow-
up was completed on 34 of the 36 children with lipoatrophy and 60 of the 64 children without 
lipoatrophy at baseline. Median follow-up time was 14.9 months (interquartile range: 14.5 to 15.6 
months). At follow-up, 9/60 children had developed new lipoatrophy, giving an incidence rate of 12% 
(CI: 5% to 20%) per person-year of follow-up. Lipoatrophy had resolved in 5/34 children, all of whom 
had no more than moderate (grade 2) lipoatrophy signs at baseline and had been switched to abacavir 
>18 months before follow-up.  
 
Discussion 
This was some of the first data from sub-Saharan Africa to show the severity and extent of 
antiretroviral-related lipoatrophy in children and was first presented at the 2011 International AIDS 
Society Conference. At the same meeting, data was presented by the NEVEREST study group in 
Johannesburg, which showed consistently greater subcutaneous fat in children on protease inhibitors 
compared to those on non-nucleoside reverse transcriptase inhibitors, and generally low 
subcutaneous fat in children on stavudine (7). They did not define a diagnostic cut-off for lipoatrophy 
and thus no prevalence figures were given. 
 
Visually obvious lipoatrophy was present in a third of pre-pubertal children on ART. Children with 
visually obvious lipoatrophy had 25-40% less extremity fat (depending on the choice of 
measurement) than HIV-infected children without lipoatrophy. Children with lipoatrophy were not 
sicker and did not start ART at a different age, compared to those without lipoatrophy. Since 
cumulative time on standard-dose stavudine is the greatest risk factor for lipoatrophy, it is not 
surprising that older children, who had amassed more stavudine exposure, had more lipoatrophy. 
Other potential confounding effects associated with the difference in age were adjusted for in the 
multivariate model.  
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Although DXA and anthropometry may be more precise measures of subcutaneous fat amount and 
distribution, a visual grading scale was chosen as the primary outcome measure in this study because 
the greatest danger of lipoatrophy in sub-Saharan Africa stems from stigmatization. Therefore, subtle 
changes in fat distribution that are not visually obvious are less relevant since they are unlikely to 
result in stigmatization.  
 
Two previous studies have found that some partial improvement of lipoatrophy may occur after drug 
switching, with the more severe cases experiencing the least improvement (12-13). In line with this, 
the 5 individuals with lipoatrophy at baseline who resolved by follow-up had all been graded as 
having no more than moderate (grade 2) changes at baseline and had been switched to abacavir more 
than 18 months earlier, during which time some improvement in subcutaneous SFT occurred.  
 
As there is evidence of a genetic determinant in lipoatrophy (17), it is important to study lipoatrophy 
specifically in sub-Saharan African populations. Our data suggest that the prevalence of visually 
obvious lipoatrophy in pre-pubertal South African children on ART is higher than the prevalence 
among most non-African cohorts (typically 10 to 20%) (18, 20-21, 33, 68). In the largest and most 
comprehensive study to date, Alam et al (4) found a 28% prevalence in a cross-sectional study of 426 
European children, including 85 pubertal and 154 post-pubertal children and 107 black children. The 
authors of that study noted that their prevalence was significantly higher than in previous paediatric 
studies, in line with our data. Since survival rates are high in medication-adherent HIV-infected 
children, and established lipoatrophy changes are largely irreversible, prevalence can be expected to 
increase progressively if incidence remains constant. Alam et al found that Caucasian rather than 
African ethnicity was a risk factor for lipoatrophy. However, none of our recruits were Caucasian and 
our pre-pubertal South African group had a higher prevalence than Alam’s cohort. This is most likely 
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due to higher rates of stavudine exposure in our context. The magnitude of this difference suggests 
that data from immigrant African populations in Europe cannot be extrapolated to populations living 
in sub-Saharan Africa and emphasizes how crucial it is to study sub-Saharan populations directly, as 
>90% of HIV-infected children live in these regions.  
 
Ten percent of the cohort reported by Alam et al was currently exposed to stavudine (4), compared to 
62% of ours. While Alam et al found an association between lipoatrophy and current stavudine 
exposure, our results go one step further to show that the risk of lipoatrophy increases progressively 
as exposure to stavudine accumulates. This finding is in line with that of the Asian cohort reported by 
Aurpibul et al, which found an increasing prevalence of fat distribution abnormalities as cumulative 
exposure to ART increased (33). This is significant since Asian cohorts have similar conditions to sub-
Saharan Africa in that malnutrition is common, access to ART for children is incomplete, and 
stavudine has been the most widely used first-line antiretroviral agent (12). 
 
Objective anthropometric and DXA measurements confirmed the clinical assessment of visually 
obvious lipoatrophy. Thus, diagnosis of lipoatrophy in African children by skilled visual assessment is 
reliable and, whilst it requires training and experience, no additional investigations are needed in a 
developing country context. Specific training to recognize lipoatrophy in children should include 
supervised practice in a clinic setting over a period of time until competence is reached to the 
satisfaction of the trainer. However, basic competence might be gained through review of an array of 
photographs of mild to moderate lipoatrophy at varying ages, combined with diligent vigilance during 
clinical practice. The authors have not studied the adequacy of photograph-based training.  
 
The prevalence of visually obvious lipoatrophy in pre-pubertal South African children on ART is 
higher than previously anticipated, affecting a third of children on ART. This is most likely due to 
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more extensive use of stavudine than elsewhere. Whilst ART is life-saving for HIV-infected children, 
surveillance and early diagnosis of lipoatrophy with appropriate drug-switches is critical. The use of 
agents associated with potentially stigmatizing face and limb changes is undesirable. The 
antiretroviral agent most commonly associated with lipoatrophy in adults is stavudine, affecting up to 
32% of patients after two years of exposure to 40mg twice daily (2). Our findings substantiate this in 
the pre-pubertal South African population.  
 
When considering the association of lipoatrophy with zidovudine exposure, it is important to 
incorporate the confounding effect of prior stavudine exposure and remember that the odds of 
finding lipoatrophy in a child exposed to stavudine for 18 months was nearly three times higher than 
finding lipoatrophy in a child not exposed to stavudine. Of the 33 children ever exposed to 
zidovudine, 18 had also been exposed to more than 18 months of stavudine therapy, of which 15 had 
lipoatrophy. By comparison, of the 15 children ever exposed to zidovudine who had not been exposed 
to at least 18 months of stavudine therapy, only 2 had lipoatrophy. Due to limited sample size, the 
effect of zidovudine exposure on lipoatrophy did not reach statistical significance after correction for 
cumulative stavudine exposure.  
 
This study has a number of limitations:  
1. Of the 190 possibly eligible patients appearing on the clinic database, 66 could not be found 
and 21 did not arrive for their study visit and either could not be traced or did not respond to 
attempts at further contact. This is not unexpected since patients in our setting live in a socio-
economically-deprived environment and patients are often unable to attend on the planned 
appointment day. Predicting the day of their visit is difficult and it often requires a number of 
attempts to meet up with the patient. Since doctor visits occur once every three months, there 
were only 3 or 4 potential visits for each patient during the 12 month study recruitment 
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window. Due to their socio-economic instability, patients often don’t keep the same cellular 
telephone number for more than a few months, and the telephone number recorded on the 
database is often out of date. In addition, the Family Clinic for HIV is based in a tertiary 
hospital and has a high turn-over rate as children are down-referred to peripheral clinics to 
make space for new referrals. The clinic’s database runs on limited funding for maintenance 
and there is often a significant lag time between clinical event and data capture. A large 
number of apparently eligible children appearing on the database may have already been 
transferred out or lost to follow-up.  
2. Although age, gender, cumulative stavudine exposure and absolute CD4 count of our sample 
were not significantly different to those who were not recruited, it is possible that some 
selection bias may have occurred. We selected subjects for enrolment who attended a routine 
clinic appointment during the study-screening period. This could represent a biased subset of 
all available subjects in our clinic population, since lipoatrophy is more likely in adherent 
patients. In addition, caregivers who had previously noticed subcutaneous fat changes in their 
children, or whose children had previously been diagnosed with lipoatrophy, may have been 
more inclined to participate. This may have falsely raised the found prevalence of lipoatrophy 
in our study.  
3. The two clinicians who performed the visual assessment could not be blinded to the children’s 
ART status, which may have biased their assessment. However, since the children were well 
known, the clinicians had a longitudinal perspective on which to base their assessment, which 
may have made their assessment more accurate.  
4. Our Family Clinic for HIV is a tertiary-hospital-based clinic in a highly urbanized 
environment, and our patient population may be dissimilar to patient populations at primary 
healthcare clinics or in less urbanized or rural settings. Our clinic population may be sicker 
and have a higher prevalence of ART-related complications, possibly leading to a higher 
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prevalence of lipoatrophy. However, the use of antiretrovirals other than stavudine is more 
common in our clinic than in less urbanized secondary or primary care settings where supply 
chains for paediatric formulations of alternative antiretroviral drugs may not be reliable. More 
common use of stavudine in those settings may lead to an even higher incidence of lipoatrophy 
than was found in our clinic population.  
5. Medical staff at our facility have great experience and thus an excellent ability to detect 
lipoatrophy at an early stage. Therefore, children at our facility may be switched to alternative 
ART earlier, resulting ultimately in less severe lipoatrophy and a greater likelihood of 
resolution after switching. This may have led to a lower prevalence of lipoatrophy in our clinic 
population compared to patient populations in primary healthcare clinics.  
6. Although DXA was requested for all recruits, as DXA is a rare facility in the developing world, 
DXA was not always available. The individuals who received a DXA scan were those who were 
present when the DXA scanner was available. The number of children who received a DXA 
scan was small and the possibility of selection bias in the DXA substudy cannot be excluded. 
 
Conclusions 
The prevalence of visually obvious lipoatrophy in pre-pubertal South African children on 
antiretroviral therapy is high, and is likely to continue rising as stavudine continues to be used 
extensively at an unnecessarily high dose. The amount of stavudine that children are exposed to 
needs review. Resources are needed to enable low- and middle-income countries to provide suitable 
paediatric-formulated alternatives to stavudine-based paediatric regimens. The standard stavudine 
dose for children may need to be re-evaluated.  Diagnosis of lipoatrophy at an early stage is important 
to avoid stigmatization. Diagnosis using visual grading requires training and experience, and DXA 
and comprehensive anthropometry are not commonly available. A simple objective screening tool is 
needed that can identify early lipoatrophy in resource-limited settings where specialized skills and 
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equipment are not available. The screening tool should detect lipoatrophy in pre-pubertal children 
before it causes stigmatizing disfigurement, allowing appropriate antiretroviral switches to be made 
early to arrest progression. The tool should require no special equipment or training and should be 
easy for primary care nurses and ancillary healthcare workers to use. 
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Table 1: Comparison of HIV-infected children with and without visually obvious lipoatrophy 
  Children with 
lipoatrophy 
N=36 
Children without 
lipoatrophy 
N=64 
Univariate 
p-value 
(two-tailed) 
Multivariate p-
value 
(two-tailed)a 
 Median age (months) at antiretroviral 
therapy (ART)  initiation, with inter-
quartile range (IQR) 
 24 (9 – 43)  19 (9 – 37)  0.74 
– 
 Median age at recruitment (months) 
(IQR) 
 89 (71 – 112)  71 (50 – 92)  0.001 
0.75 
 Gender: Male / Female  21 (58%) /  
    15 (42%) 
 31 (48%) /  
    33 (52%) 
 0.41 
– 
 Median nadir absolute CD4 before ART 
initiation (IQR)  
 694 (439 – 798)  802 (447 – 1131)  0.29 
– 
 Median nadir CD4% before ART 
initiation (IQR) 
 15% (7 – 21%)  17% (14 – 25%)  0.05 
– 
 Absolute CD4 at recruitment (IQR)  1213 (919 – 1556)  1129 (792 – 1524)  0.57 
– 
 CD4% at recruitment (IQR)  37% (30 – 40%)  31% (26 – 37%)  0.03 
0.34 
 Median log10 viral load at recruitment 
(IQR) 
 1.85 (1.60 – 2.54) 1.85 (1.60 – 2.54)  0.10 
– 
 Number with HIV RNA viral load below 
400copies/ml 
 35 (97%)  55 (86%)  0.07 
– 
 Maximum WHO clinical stage ever 
reached:  
 1 / 2 / 3 / 4 
 25% / 11% / 39% / 
25% 
 17% / 9% / 46%  
/ 28% 
 0.78 
– 
 Median weight for age Z-score (IQR)   -1.0 (-1.8 – -0.5)  -1.0 (-1.6 – -0.3)  0.39 
– 
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 Median height for age Z-score (IQR)  -1.1 (-2.0 – -0.5)  -1.3 (-2.3 – -0.8)  0.49 
– 
 Median body mass index Z-score (IQR)  -0.6 (-1.1 – 0.0)  -0.2 (-0.8 – 0.6)  0.008 
– 
 Number on 2nd line therapy, defined as  
 switch of ≥2 antiretroviral drugs (%) 
 3 (8%)  4 (6%)  0.58 – 
 Any antiretroviral exposure, median 
months  (IQR) 
 56 (44 – 75)  43 (25 – 60)  0.002 0.52 
 Number ever exposed to stavudine (%)  35 (97%)  53 (83%)  0.04 – 
 Stavudine, median months (IQR)   41 (27 – 48)  30 (7 – 49)  0.02 0.002b 
 Number ever exposed to zidovudine (%)  17 (47%)  16 (25%)  0.02 – 
 Zidovudine, median months (IQR)  12 (5 – 21)  0 (0 – 0) c  0.56 – 
 Lamivudine, median months (IQR)   52 (41 – 72)  41 (25 – 58)  0.01 0.66 
 Number ever exposed to lopinavir/r (%)  22 (61%)  50 (78%)  0.07 – 
 Lopinavir/r, median months (IQR)   26 (0 – 56)  36 (6 – 51)  0.58 0.82 
 Number ever exposed to efavirenz (%)  17 (47%)  19 (30%)  0.09 – 
 Efavirenz, medianc months (IQR)  0 (0 – 44)  0 (0 – 4)  0.003 0.48 
a Variables with dashes were not included in the multivariate model 
b Adjusted odds ratio: 1.9 (95% CI: 1.3 - 2.9) for each additional year of accumulated exposure 
c Since fewer than half of the subjects in these groups had been exposed to these drugs, the median 
exposure was 0 months. Mean efavirenz exposure was 23 months in children with lipoatrophy 
versus 7 months in children without lipoatrophy. Mean zidovudine exposure was 8 months in 
children with lipoatrophy versus 10 months in children without lipoatrophy. 
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Table 2: Anthropometric measurements in children with and without visually obvious lipoatrophy, 
adjusted for age and sex. P-value compares HIV-infected children with and without 
lipoatrophy 
 Children with 
lipoatrophy, 
N=36 
Children without 
lipoatrophy, 
N=64 
HIV-uninfected 
local population 
norms, N=57 
p-value, 
adjusted for 
age and sex 
(two-tailed) 
Biceps skin-fold thickness (SFT), 
mm, mean with 95% confidence 
interval (95% CI) 
4.2 (3.6 – 4.7) 5.3 (4.9 – 5.7) 5.5 (5.0 – 5.9) 0.002 
Triceps SFT, mm, mean (95% CI) 7.1 (6.2 – 7.9) 8.9 (8.3 – 9.6) 8.7 (8.1 – 9.4) <0.001 
Torso-to-arm SFT ratio: mean 
(95% CI)* 
1.05 (0.96 – 1.14) 0.88 (0.81 – 0.94) 0.84 (0.78 – 0.91) 0.002 
Waist-to-hip circumference ratio: 
mean (95% CI) 
0.97 (0.96 – 0.99) 0.95 (0.93 – 0.96) 0.91 (0.90 – 0.93) 0.009 
*Torso to arm SFT ratio = (subscapular + iliac crest SFT) / (biceps + triceps SFT) 
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Table 3: Dual Energy X-ray Absorbtiometry measurements in children with and without visually 
obvious lipoatrophy. P-value compares HIV-infected children with and without lipoatrophy 
 Children with 
lipoatrophy, N=15 
Children without 
lipoatrophy, N=27 
HIV-uninfected 
local population 
norms, N=34 
p-value, 
adjusted for 
age and sex 
(two-tailed) 
Limb fat versus limb lean ratio: 
mean with 95% confidence interval 
(95% CI) 
0.36 (0.25 – 0.46) 0.62 (0.54 – 0.70) 0.63 (0.56 – 0.70) <0.001 
Limb fat versus total body weight 
ratio: mean (95% CI) 
9.9 (8.5 – 11.4) 13.7 (12.7 – 14.8) 14.7 (13.7 – 15.7) <0.001 
Limb fat versus body mass index 
ratio: mean (95% CI) 
0.12 (0.10 – 0.13) 0.15 (0.14 – 0.17) 0.17 (0.16 – 0.19) 0.001 
Total limb fat, kg, mean (95% CI) 1.7 (1.4 – 2.1) 2.3 (2.1 – 2.6) 2.7 (2.4 – 2.9) 0.01 
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Table 4: Lipoatrophy grading scores at baseline and at follow-up 
Baseline Follow-up 
Maximum lipoatrophy 
score 
n 
Maximum lipoatrophy 
score 
n 
0 58 
0 39 
1 11 
2 5 
3 0 
1 6 
0 1 
1 0 
2 3 
3 1 
2 24 
0 2 
1 3 
2 13 
3 4 
3 12 
0 0 
1 0 
2 6 
3 6 
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Figure 1: Stigmatizing lipoatrophy in a child – Front view 
 
Figure 2: Stigmatizing lipoatrophy in a child – Side view 
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Both photo’s are the author’s own, and have been previously printed in Innes S, Levin L, Cotton MF. 
Lipodystrophy syndrome in HIV-infected children on HAART. South African Journal of HIV 
Medicine 2009; 10(4): 76-80. (NIHMS218910) (PMCID2919754). They are reprinted here 
with permission from South African Journal of HIV Medicine. Consent for publication of both 
photo’s was obtained from the relevant legal guardian.  
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Figure 3: Lipoatrophy grading scores at baseline and at follow-up 
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Chapter 2 
Biceps skin-fold thickness may detect and predict early lipoatrophy in 
HIV-infected pre-pubertal children on antiretroviral therapy   
 
Abstract  
Background: The prevalence of lipoatrophy in children on antiretroviral therapy in Southern Africa is 
high, affecting around a third of children. Early diagnosis of lipoatrophy is essential for effective 
intervention to arrest progression.  
Methods: This was a sub-analysis performed on data from a previous study wherein pre-pubertal 
children on antiretroviral therapy were recruited from a hospital-based family HIV clinic in Cape 
Town and followed up prospectively. Lipoatrophy was identified and graded by consensus between 
two HIV pediatricians. A dietician performed anthropometric measurements of trunk and limb fat. 
Anthropometric measurements in children with and without lipoatrophy were compared using 
multivariable linear regression adjusting for age and gender. The most discerning anthropometric 
indicators of lipoatrophy underwent Receiver Operating Characteristic curve analysis.  
Results: 36/100 recruits had lipoatrophy at baseline and a further 9 developed lipoatrophy by 15 
month follow-up. A biceps skin-fold thickness <5mm at baseline had a sensitivity of 89% (CI: 67-
100%) and a specificity of 60% (CI:  46-75%) for predicting which children would go on to develop 
lipoatrophy by 15 month follow-up. Negative and positive predictive values were 97% (CI: 91-100%) 
and 32% (CI: 14-50%). 
Conclusion: Biceps skin-fold thickness <5mm in pre-pubertal children exposed to thymidine 
analogue-based antiretroviral therapy may be a useful screening tool to identify children who are 
likely to go on to develop lipoatrophy.   
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Introduction 
Long-term use of antiretroviral therapy (ART), particularly the nucleoside reverse transcriptase 
inhibitors stavudine and zidovudine, may result in disfiguring loss of subcutaneous fat, termed 
lipoatrophy. While programmatic changes are starting to  phase out stavudine use in adults, 
stavudine remains the most commonly used antiretroviral for HIV-infected children in sub-Saharan 
Africa (55, 80). Even in South Africa, while children initiating ART after 2010 have been initiated on 
abacavir, the majority of children treated for HIV remain on stavudine, and current guidelines state 
that children taking stavudine should continue unless side effects develop, at which stage the child is 
switched to abacavir (81). In most other sub-Saharan African countries the cost of abacavir remains 
prohibitive and the most common alternative is zidovudine, which also causes lipoatrophy albeit less 
severely (2, 60). 
 
The prevalence of lipoatrophy in children on ART appears to be rising over time: Studies from 2005 
and 2006 estimated the prevalence of lipoatrophy at 8% to 11% (18-19) whereas the most recent 
studies have found a prevalence of around 28% (4). Accumulation of cases is not surprising since 
lipoatrophy changes may persist despite switching of ART regimen, and survival rates are high in 
medication-adherent children who are at highest risk of lipoatrophy. Recently we have shown that the 
prevalence of lipoatrophy in pre-pubertal African children on any ART in South Africa is 36% (82).  
 
Lipoatrophy looks very similar to AIDS wasting syndrome, termed “Slims disease” throughout Africa, 
and may confer the same stigmatization. In contrast to the developed world, stigmatization due to 
HIV in the communal cultures of sub-Saharan Africa may lead to loss of housing, loss of employment 
or livelihood, denial of schooling, denial of healthcare, secondary stigmatization of family members 
and physical violence (9-10). Patients who develop recognizable ART-related fat distribution 
abnormalities may become non-adherent to ART in order to avoid stigmatization (83-84), which will 
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result in declining CD4 cells, development of opportunistic infections and possibly death. This is 
particularly true of adolescents who are piquantly concerned about body image and social acceptance, 
and who may become non-adherent even in the absence of ART-related body changes (85). In 
previous reports, partial recovery occurred in the least severely affected individuals (12, 86). Severe 
lipoatrophy may not be reversible (13-14, 86). This is understandable since lipoatrophy is due to 
progressive apoptosis of adipocytes, which do not recover (15), as opposed to nutritional wasting 
where adipocyte fat stores shrink but the cell survives. However, stigmatization only occurs when 
lipoatrophy is easily recognizable by the broader community.  Communities with the highest 
prevalence of HIV are the most likely to recognize HIV-related or ART-related body changes. 
Southern Africa has the highest HIV prevalence in the world (87). Stigmatization can be prevented if 
lipoatrophy is diagnosed early and appropriate ART switches are made, which will arrest lipoatrophy 
progression (14).  
 
Diagnosis of early lipoatrophy is difficult. While an objective case definition for lipoatrophy has been 
established for adults (66), this has not been validated in children and the international gold standard 
for diagnosing lipoatrophy in children is the skilled visual assessment of subcutaneous limb and face 
fat performed by experienced pediatric HIV clinicians who have been specifically trained to do this 
(21). In developed countries, serial magnetic resonance imaging (MRI) and serial dual emission X-ray 
absorptiometry (DXA) scanning are available to monitor the amount and distribution of 
subcutaneous fat in HIV-infected children exposed to thymidine analogue ART. Radiographic 
methods are not feasible in resource-constrained settings and pediatric-trained HIV specialists are 
scarce. A simple screening tool is needed to detect lipoatrophy in pre-pubertal children before it 
causes stigmatizing disfigurement, allowing appropriate antiretroviral switches to be made early to 
arrest progression. The tool should require minimal equipment or training and should be easy for 
primary care nurses and ancillary healthcare workers to use. Preliminary evidence from two previous 
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studies has indicated that anthropometric measures of subcutaneous fat might be able to differentiate 
HIV-infected children with and without noticeable lipoatrophy (19, 68). However, those studies had a 
number of limitations: Hartman et al included only 4 children with lipoatrophy, all of whom were 
pubertal, and data was presented as median z-scores without an indication of range (68). Dzwonek et 
al included only 5 children with lipoatrophy and did not record pubertal stage (19). Both studies 
relied on a visual assessment to identify lipoatrophy. 
 
The aim of the current study was to develop an anthropometric screening tool to detect lipoatrophy in 
pre-pubertal children before it causes stigmatizing disfigurement. We performed a second study to 
test the impact of imprecision in anthropometric measurements performed by an inexperienced 
healthcare worker on the diagnostic performance of the screening tool. 
  
Methods 
This was a sub-analysis performed on data from the study described in chapter 1, wherein children 
who were 3-12 years old, on antiretroviral therapy and pre-pubertal were recruited between February 
2010 and January 2011. Pre-pubertal status was defined as Tanner stage 1 for genital and pubic hair 
development in boys, and Tanner stage 1 for pubic hair development with Tanner stage 1 or 2 for 
breast development in girls. Using review of our electronic health record database, we identified 190 
patients that potentially met inclusion criteria. Of these, 124 attended clinic during the study period 
and could be approached for screening. A total of 121 provisionally agreed to participate, however, 21 
did not attend the study visit nor did they respond to attempts at further contact. 100 subjects were 
finally recruited. There was no difference in demographic characteristics of the 100 enrolled subjects 
and the 90 who were not recruited (p>0.20 for age, gender, cumulative stavudine exposure and CD4, 
data not shown). Sampling bias is therefore unlikely. 
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Lipoatrophy was identified and graded by consensus between two experienced HIV pediatricians 
using the following lipoatrophy grading scale as defined by existing literature (33, 66, 68): 0 – No fat 
changes; 1 – Possible minor changes, noticeable only on close inspection; 2 - Moderate changes, 
readily noticeable to an experienced clinician or a close relative who knows the child well; 3 – Major 
changes, readily noticeable to a casual observer.  Face, arms, legs and buttocks were assessed for loss 
of subcutaneous fat resulting in abnormally prominent limb veins, a lean, muscular appearance of 
limbs and face, and loss of gluteal fat pad with reduction in buttock size and loss of gluteal contour. 
Where the assessment of the two investigators did not concur, the change was graded as the lower 
score. Lipoatrophy was defined as a score of 2 or 3. Lipoatrophy assessment was repeated at 15 month 
follow-up. The duration and details of prior ART and demographics were recorded from our 
electronic health record database. HIV RNA values and CD4 values were extracted from our central 
electronic laboratory results server. Doses of antiretroviral drugs followed nationally prescribed 
protocols. For stavudine this meant a minimum of 1mg/kg twice daily rounded up to the nearest 
practical dose (88). A professional dietician performed formal dietary assessment and 
anthropometric measurements of trunk and limb fat using a non-stretchable tape-measure (model 
number F10-02DM, Muratec KDS Corporation, Kyoto, Japan), a high-precision Harpenden® skin-
fold caliper (Baty International, West Sussex, United Kingdom), a ShorrBoard® stadiometer (Shorr 
Productions, Maryland, USA), and a precision weighing scale (model number UC-321, A&D 
Company, Tokyo, Japan) which was calibrated daily. The stated accuracy of the Harpenden® skin-
fold caliper is 99%, with a dial graduation of 0.2mm and repeatability of 0.2mm (89). Measurements 
included mid-upper arm circumference (MUAC), mid-thigh circumference, chest circumference, 
waist circumference, hip circumference, biceps skin fold thickness (SFT), triceps SFT, iliac crest SFT, 
sub-scapular SFT, mid-thigh SFT, height and weight. All anthropometric measurements were 
performed three times and averaged. The following ratios were derived: waist to hip circumference 
ratio; body mass index; torso to arm SFT ratio ([subscapular + iliac crest SFT] / [biceps + triceps 
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SFT]); waist-to-MUAC ratio, and weight-to-MUAC ratio. Diet assessment variables included in the 
analysis were total daily carbohydrate consumption, total daily fat consumption and total daily calorie 
consumption. The dietician graded each as inadequate, appropriate or excessive. Data was stored in a 
secure electronic database using REDCap® software (https://redcap.vanderbilt.edu, Vanderbilt 
University, Nashville, Tennessee). 
 
Analysis 
Baseline data were compared between patients with and without lipoatrophy using T-test for 
continuous variables and Chi-square test for categorical variables.  Univariate Spearman's correlation 
analysis was performed between maximum lipoatrophy grading score and each of the anthropometric 
measures. To adjust for age and gender, multiple linear regression models were conducted to assess 
the associations between each of the anthropometric measures and 4-point lipoatrophy grading 
scores. SFT data was log-transformed for analysis. The model used the anthropometric measure as 
the dependent variable and lipoatrophy grading score, age and gender as the independent variables. 
Partial Spearman's correlations were calculated between the 4-point lipoatrophy score and each of 
the anthropometric measures adjusted for age and gender, using the variance-covariance matrix.  
 
Receiver Operating Characteristic (ROC) curve analysis was performed on anthropomorphic 
variables that were significant in the multiple regression analyses. ROC analyses (using pROC 
package in R) were conducted to compare the performance of these anthropometric measures in 
predicting lipoatrophy. Two sets of analyses were performed. The first used baseline anthropometric 
measures to predict baseline prevalent lipoatrophy diagnosis. The second used baseline 
anthropometric measures to predict the 1-year incident lipoatrophy outcome. The latter analysis only 
included patients without lipoatrophy at baseline. For each variable, a threshold was determined at 
which the values of sensitivity and specificity for detecting early lipoatrophy were optimized. Positive 
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predictive value (PPV) and negative predictive value (NPV) were calculated. For each of these 
anthropometric measures, empirical ROC curves and partial AUC (pAUC between 80% and 100% 
sensitivity) with correction by McClish (90) were calculated. 95% confidence intervals were 
determined by bootstrap for ROC AUC, sensitivity and specificity, and by Gaussian approximation for 
NPV and PPV. Statistical analyses were performed using R version 2.10.0 (Bell Laboratories, New 
Jersey).    
 
This study was designed in accordance with the guidelines of the International Conference on 
Harmonization for Good Clinical Practice and with the Declaration of Helsinki (version 2000), and 
approved and monitored by the Ethics Committee for Human Research of the Stellenbosch 
University, approval reference number N08/11/349. Written informed consent was obtained from 
each caregiver prior to participation, and informed assent was obtained from capable children. All 
patient-related data was stored in a password-secured database under a patient identifying number 
and kept strictly confidential. 
 
Results 
Baseline anthropomorphic measures that were significantly different (p< 0.001) between those with 
versus without lipoatrophy were biceps SFT (3.8± 1.1 [mean, standard deviation] versus 5.3 ± 2.2, 
respectively), triceps SFT (6.6 ± 1.9 vs. 9.0 ± 3.0) and torso-to-arm SFT ratio (1.1 ± 0.3 vs. 0.9 ± 0.3) 
while body mass index Z-score and waist-to-hip circumference ratio were not different between 
groups. Separate multivariable models, using the three significant SFT measures as the dependent 
variables and the full 4-point lipoatrophy score, age and sex as independent variables, showed 
significant correlations between SFT and lipoatrophy score after adjusting for age and gender. When 
adjusted for age and gender, partial correlation coefficients between the three significant SFT 
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measures and 4-point lipoatrophy score were 0.33 (biceps, p=0.0006), 0.37 (triceps, p=0.0001) and 
0.39 (torso-to-arm ratio, p=0.0001).  
 
In order to determine the optimal differentiating anthropometric variable, partial ROC area-under-
the-curve (pAUC), for 80%-100% sensitivity, were done; these were nominally higher for biceps (0.7; 
95% CI: 0.59 – 0.80) than for triceps or torso-to-arm ratio SFT (0.68 and 0.66 respectively, figure 1).  
As the biceps measurement is also clinically easier to perform, this was selected as the optimal 
measure.  The total ROC area-under-curve value was 0.75 (CI: 0.64 – 0.84). An ROC area-under-
curve measurement of 0.5 for a diagnostic test indicates zero diagnostic power, whereas a value of 1.0 
indicates perfect diagnostic power. The biceps SFT ROC curve revealed that the threshold value for 
biceps SFT that gave optimal screening sensitivity and specificity for differentiating children with and 
without lipoatrophy at baseline was 4.85mm. A clinically measurable biceps SFT threshold of 5mm 
had a sensitivity of 89% (CI: 78 – 97%) and a specificity of 61% (CI: 48 – 72%) to detect lipoatrophy 
at baseline. NPV was 90% (CI: 80 – 99%) and PPV was 57% (CI: 42 – 68%). 
 
Follow-up was completed on 34 of the 36 children with lipoatrophy and 60 of the 64 children without 
lipoatrophy at baseline. Median follow-up time was 14.9 months (interquartile range: 14.5 – 15.6 
months). At follow-up, 9/60 children had developed new lipoatrophy, giving an incidence rate of 12% 
(CI: 5 – 20%) per person-year of follow-up. Lipoatrophy had resolved in 5/34 children, all of whom 
had been switched to abacavir more than 18 months before and had no more than moderate (grade 2) 
lipoatrophy signs at baseline.  
 
In children without lipoatrophy at baseline, ROC analysis of baseline biceps SFT revealed an area-
under-curve value of 0.83 (CI: 0.67 – 1.00) and a partial ROC area-under curve value for sensitivity 
between 80% and 100% of 0.69 (CI: 0.54 – 0.93) for predicting which children would go on to 
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develop lipoatrophy by 15 month follow-up (Figure 2). In comparison, the ability of triceps SFT to 
predict lipoatrophy at follow-up was limited, with a partial ROC area-under-curve value for 
sensitivity between 80% and 100% of 0.56 (CI: 0.46 – 0.91). Figure 2 shows ROC curves of biceps 
SFT, triceps SFT and torso-to-arm SFT ratio to predict new lipoatrophy at follow-up. In children 
without lipoatrophy at baseline, a baseline biceps SFT <5mm yielded a sensitivity of 89% (CI: 67 – 
100%) and a specificity of 60% (CI: 46-75%) for predicting which children would go on to develop 
lipoatrophy. NPV was 97% (CI: 91 – 100%) and PPV was 32% (14 – 50%). Post-test probabilities were 
as follows: In the presence of a negative test, the post-test probability of developing lipoatrophy by 15-
month follow-up was 0.10 (CI: 0.02 – 0.18), whereas the probability of not developing lipoatrophy 
was 0.91 (CI: 0.84 – 0.99). In the presence of a positive test, the post-test probability of developing 
lipoatrophy by 15-month follow-up was 0.59 (CI: 0.46 – 0.71), whereas the probability of not 
developing lipoatrophy was 0.41 (CI: 0.29 – 0.54).  
 
Only three recruits had Tanner stage 2 breast development at baseline. Repeating the analyses 
without these three children marginally improved the performance of the screening tool both at 
baseline and at follow-up. Proportions of ethnic subgroups were very similar between those with and 
without lipoatrophy (p>0.30). 
 
Discussion 
Children with and without lipoatrophy had similar immunologic and clinical presentation at ART 
initiation and at recruitment (p >0.2 for absolute CD4 and WHO clinical staging). They did not start 
ART earlier and a similar proportion was on second-line ART. The median age of children with 
lipoatrophy was higher than that of children without lipoatrophy (7.4 versus 5.9 years, p=0.001). This 
difference in age was expected since the risk of lipoatrophy increases with cumulative ART use (82), 
which increases with age.  
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Some partial improvement of lipoatrophy may be experienced after drug switching, with the more 
severe cases experiencing the least improvement (12). The biceps SFT at baseline was less informative 
for detecting existing cases than for predicting new cases at follow-up. Individuals known to have 
lipoatrophy prior to recruitment had been switched to abacavir months or years before recruitment 
and may have experienced some improvement in subcutaneous SFT before recruitment as a result of 
the switch. This may explain the limited performance of the screening tool in detecting lipoatrophy at 
baseline. The ROC analysis for predicting new cases at follow-up may be more helpful since new cases 
at follow-up had not been influenced by interventional drug switches.  
 
The ROC analyses at baseline did not confirm that any of the three SFT contenders (biceps, triceps 
and arm-to-trunk ratio) was statistically superior to the others.  However, the biceps SFT technique is 
the most simple to perform, and biceps SFT measurements had the least inter- and intra-observer 
variability. These strengths led us to choose biceps SFT over triceps SFT and torso-to-arm SFT ratio. 
Using a threshold of 5mm for biceps SFT yields a high sensitivity and NPV, making it effective for 
screening. The relatively low specificity is clinically acceptable; as the next step after screening is 
referral, not change of therapy. The screening tool can be employed by nurses and ancillary 
healthcare workers who can then refer children with suspected early lipoatrophy to pediatric HIV 
doctors for confirmation and antiretroviral switching as necessary. Experienced HIV pediatricians 
who have been specifically trained to identify early lipoatrophy will typically use the formal visual 
grading scale described above to confirm the diagnosis.  
 
Lipoatrophy does not occur in all children exposed to ART (4, 21, 33). Some show no signs of fat 
changes despite many years of stavudine or zidovudine exposure, whereas others develop lipoatrophy 
within 18 months of ART initiation (86). This variation may be due to genetic differences that 
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increase or decrease an individual’s susceptibility to lipoatrophy (17, 34-35), which would explain 
why viral load did not clearly differentiate between children with and without lipoatrophy in our 
study. Ethnic differences may also play a role (4). In the face of this unpredictability, our screening 
tool provides an objective, easy-to-use method to identify children who may be developing 
lipoatrophy.  
 
The current study was performed using a Harpenden® calliper, which although highly precise, is 
expensive ($340). A Slimguide® skin-fold calliper (Vancouver: Rosscraft) is marginally less precise 
(repeatability 0.5mm (91)) but is cheap ($20) and durable, and may be a more suitable device to roll 
out in resource-limited primary healthcare settings in sub-Saharan Africa. Before implementation of 
the Slimguide® can be recommended, a further study is needed in which repeated measurements are 
performed by an experienced anthropometric dietician using both the Harpenden® and Slimguide® 
callipers to quantify the additional imprecision contributed by using the less precise device. 
 
For broad implementation of this screening tool, a brief written description of how to perform a 
biceps SFT measurement may be all the training that is necessary. For children on ART, the effort 
required to perform a single annual biceps SFT measurement is likely to be logistically feasible even 
in busy community healthcare clinics. Serial annual biceps SFT measurements also give the added 
benefit of identifying changes from baseline: A biceps SFT that has dropped from a higher baseline to 
below 5mm, in the absence of an obvious nutritional or other cause, is probably a more convincing 
indication of impending lipoatrophy than a static measurement below 5mm.  
 
Inclusion of girls with Tanner stage 2 breast development was allowed in this study since early 
minimal thelarche is not uncommon in very young girls in whom it does not herald the onset of true 
puberty (92-93). However, since the presence of early breast tissue may be associated with a higher 
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body fat proportion, the analyses were repeated without the children with stage 2 breast 
development. Only three of the 100 recruits had Tanner stage 2 breast development at baseline, and 
repeating the analyses without the three children in fact marginally improved the performance of the 
screening tool.  
 
Since proportions of ethnic subgroups were very similar between those with and without lipoatrophy, 
it is unlikely that ethnicity confounded our results.  
 
Our data on the use of biceps SFT with a cut-off of 5mm as a screening tool for lipoatrophy has a 
number of limitations:  
1. These findings apply only to pre-pubertal children between 3 and 12 years of age. While this 
period of life has relatively little fluctuation in SFT and body fat distribution (94), age and 
gender do have some impact on global subcutaneous fat and biceps SFT. Our limited sample 
size did not allow stratification of ROC cut-off thresholds by age or gender. It is possible that 
the most appropriate diagnostic cut-off value may be different for younger versus older 
children and for boys versus girls. Converting biceps SFT to an age- and gender-related 
percentile would adjust for these differences, however, calculation and interpretation of 
percentiles is complex, particularly for the minimally-trained primary care nurses and 
ancillary healthcare workers for whom the screening tool is intended. In addition, population 
reference charts for biceps SFT in African children 3 to 12 years of age have not previously 
been compiled and building percentile charts de novo would be difficult. Change in biceps SFT 
over time from each individual’s own baseline may be a more useful marker of impending 
lipoatrophy, and analysis of longitudinal data from this cohort is underway. 
2. It is important for clinicians to keep in mind that the onset of puberty will substantially alter 
subcutaneous fat amount and distribution due to the influence of sex hormones, and an 
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absolute value is unlikely to be useful in that setting. For pubertal children, a change in biceps 
SFT percentile should be investigated as a more appropriate indicator of impending 
lipoatrophy.  
3. While biceps SFT is a reasonable surrogate measure of global subcutaneous fat, it does have a 
non-Gaussian population distribution, with percentile lines above the median being more 
widely spaced than percentile lines below the median. This suggests that biceps SFT is more 
variable in fatter children than thinner children. In addition, the accuracy of SFT callipers is 
reduced at higher readings. However, lipoatrophy is typically a condition of thinner children in 
whom these limitations have the least impact.  
4. The current study had a limited sample size, resulting in broad confidence intervals and 
possibly misleading results. A larger study is needed to confirm these findings. Where this 
study is repeated, it may be wise to include a control group of ART-naïve children of similar 
ethnicity, age, gender, socio-economic setting and WHO clinical stage whose baseline body 
mass index is normal for age and whose weight z-score has remained stable for the 12 months 
preceding recruitment.  
5. The low specificity may lead to a significant number of unnecessary referrals, which may 
overburden secondary referral services.  
6. Precision of biceps skin-fold thickness is technique-dependent, which requires some training. 
An inconsistent method of measurement may lead to increased intra-observer variability. 
Differences in method between healthcare workers may lead to increased inter-observer 
variability. Both intra- and inter-observer variability may have the consequence that a patient’s 
change in biceps skin-fold thickness from baseline may go unnoticed.  
7. Although durable, if the Slimguide® calliper is used, the spring strength will eventually 
deteriorate which may not be obvious and may lead to continued use when the calliper should 
be replaced, resulting in inaccurate and possibly misleading measurements.  
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8. Reliance on an objective measurement may lead to reduced clinical vigilance on the part of 
primary healthcare staff, particularly in busy clinics where patient burdens are large.  
9. The high sensitivity may falsely reassure healthcare workers, leading to missed cases. This 
screening tool should not replace diligent attentiveness during routine follow-up.  
10. Specificity and PPV are limited and confirmation of suspected lipoatrophy using visual grading 
assessment by a skilled operator remains necessary.  
11. Adherence was not measured or correlated with lipoatrophy, and this was a weakness of the 
current study.  
12. This screening tool is not appropriate for a child who is clearly non-adherent to ART and 
developing AIDS wasting syndrome, or is severely malnourished. This does not limit the 
usefulness of the screening tool since cumulative ART exposure is the most potent risk factor 
for lipoatrophy (86), and it follows that children who are persistently non-adherent are least 
likely to develop slowly-progressive cumulative side effects like lipoatrophy. At-risk children 
are typically those who turn up reliably for their follow-up visits and whose caregivers follow 
instructions diligently. As a result, implementation of the screening tool at primary healthcare 
level is likely to reach the target population.     
 
Conclusion 
A biceps SFT of <5mm in HIV-infected pre-pubertal children exposed to thymidine analogue-based 
ART may be an objective, relatively easy-to-use screening tool to identify children who currently have 
or may progress to develop lipoatrophy, allowing appropriate antiretroviral drug switches to be made 
at an early stage, which will arrest progression and avoid stigmatizing disfigurement. However, a 
larger study is needed to confirm these findings before the screening tool is implemented.  
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Figure 1: ROC curves of biceps SFT (solid line), triceps SFT (dashed line), and torso-to-arm SFT 
ratio (dotted line) to detect prevalent lipoatrophy at baseline, n = 97. The horizontal light grey shape 
corresponds to the pAUC region. The pAUC of biceps SFT with 95% confidence interval is printed in 
the middle of the plot. The best threshold of 4.8mm with corresponding specificity (60.7%) and 
sensitivity (88.9%) for biceps SFT is also located in the plot.  
 
ROC = Receiver Operating Characteristic curve; SFT = skin-fold thickness; pAUC = partial area-
under-the-curve for sensitivity between 80% and 100%. 
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Figure 2: ROC curves of biceps SFT (solid line), triceps SFT (dashed line), and torso-to-arm SFT 
ratio (dotted line) to predict which children will go on to develop new lipoatrophy by 15 month 
follow-up, n = 58. The horizontal light grey shape corresponds to the pAUC region. The pAUC of 
biceps SFT with 95% confidence interval is printed in the middle of the plot. The best threshold of 
5mm with corresponding specificity (64.6%) and sensitivity (88.9%) for biceps SFT is also located in 
the plot.  
 
ROC = Receiver Operating Characteristic curve; SFT = skin-fold thickness; pAUC = partial area-
under-the-curve for sensitivity between 80% and 100%.  
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Chapter 3 
Substudy to determine the precision of anthropometric measurements 
performed by an inexperienced observer 
 
This substudy was performed together with Eva Schulte-Kemna. 
 
Abstract  
Background: The precision of anthropometric measurements performed by an inexperienced 
healthcare worker may influence the performance of an anthropometric screening tool for 
lipoatrophy in pre-pubertal children on antiretroviral therapy in Southern Africa.  
Methods: Pre-pubertal children were recruited from a hospital-based family HIV clinic in Cape Town. 
Anthropometric measurements were performed separately by an inexperienced observer and an 
experienced research dietician on the same children on the same day using the same equipment, 
without observation or communication between them. Mean absolute pair-wise differences were 
calculated for each anthropometric variable, and the difference was then incorporated into the 
threshold anthropometric values used by the screening tool, in order to assess how the difference in 
precision might impact the effectiveness of the screening tool.  
Results: Measurements were successfully completed on 69 children. The mean absolute pair-wise 
difference in biceps skinfold measurement was less than 1mm. Incorporating this imprecision into 
the screening tool, the sensitivity, specificity, predictive values and likelihood ratios of the screening 
tool were only marginally impacted. 
Conclusion: The variation in precision of anthropometric measurements performed by an 
inexperienced healthcare worker only marginally impacted performance of the screening tool. 
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Aim 
To assess the precision of anthropometric measurements performed by an inexperienced observer 
and examine how the imprecision might impact the performance of the screening tool.  
 
Method 
Anthropometric measurements performed by an inexperienced observer (Eva Shulte-Kemna) were 
compared to measurements performed by a highly skilled and experienced research dietician as a 
gold standard. Before the study began, the inexperienced observer received basic instruction on the 
anthropometric method for each measurement. Measurements were then performed separately by 
the inexperienced observer and the research dietician on the same children on the same day using the 
same equipment used in the parent study, without observation or communication between the 
research dietician and the inexperienced observer. Coefficients of variation were calculated. For each 
anthropometric variable, the difference between the inexperienced observer’s measurement and the 
research dietician’s measurement were calculated. This difference was then incorporated into the 
threshold anthropometric values used by the screening tool, in order to assess how the difference in 
precision might impact the effectiveness of the screening tool.  
 
Results 
77 children from a local paediatric clinic were recruited between April and June 2009 (72 HIV-
infected and 5 HIV-uninfected).  These subjects had a median age of 3.0 years (interquartile range 
2.0 – 3.8 years) and 37/77 were female. Two subsequently refused to co-operate with any 
measurements and six refused SFT measurements. SFT measurements were successfully completed 
on 69 children. The measured differences between the inexperienced observer and the research 
dietician are presented in table 1. The mean absolute difference in biceps SFT measurement between 
the inexperienced observer and the research dietician was 0.8mm. Taking this variability into 
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account, the sensitivity, specificity, positive predictive value, negative predictive value, positive 
likelihood ratio, and negative likelihood ratio of biceps SFT thresholds of <4mm and <6mm were 
calculated in order to determine how the variability in precision might affect the performance of the 
screening tool for predicting which children would have lipoatrophy at 15 month follow-up (table 2).  
 
Anthropometric measurements had been performed three times and averaged. Table 3 uses the mean 
absolute difference between the three values to calculate the intra-observer variability for the 
inexperienced observer compared to the experienced research dietician. The intra-observer variability 
of the inexperienced observer compared favourably to that of the experienced research dietician. 
 
Conclusion 
The variation in precision of measurements performed by an inexperienced healthcare worker only 
marginally impacted performance of the screening tool. 
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Table 1: Precision of anthropometric measurements performed by an inexperienced observer 
compared to an experienced research dietician (inter-observer variability) 
N = 69 
  
Measurements 
performed by 
inexperienced observer 
Measurements 
performed by 
experienced research 
dietician 
Measured pairwise 
absolute difference 
between inexperienced 
observer and research 
dietician 
Mean SD CV (%) Mean SD CV (%) Mean SD 
Waist circumference (cm) 50.4 3.9 8% 50.1 3.3 7% 0.9 0.9 
Hip circumference (cm) 49.7 3.8 8% 49.1 7.6 15% 1.7 1.5 
Mid-upper arm 
circumference (cm) 15.7 1.8 11% 15.9 1.3 8% 0.5 0.4 
Triceps SFT (mm) 9.1 3.4 38% 9.2 2.2 24% 0.9 0.9 
Biceps SFT (mm) 5.9 3.8 64% 6.0 1.5 26% 0.8 0.6 
Subscapular SFT (mm) 6.5 4.1 64% 6.3 1.7 27% 0.5 0.4 
Iliac crest SFT (mm) 8.2 4.5 54% 6.7 2.9 44% 1.7 1.5 
SFT=skin-fold thickness; CV=coefficient of variation; SD=standard deviation
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Table 2: Effectiveness of biceps skin-fold thickness (SFT) threshold of <5mm with variations in 
precision of +/-1mm, for predicting any lipoatrophy at 15 month follow-up (incorporating resolved 
cases, persistent cases and new cases), n = 94. (95% confidence intervals are given in parentheses) 
Biceps SFT 
threshold 
Sensitivity Specificity 
Positive 
predictive 
value 
Negative 
predictive 
value 
<4mm 
68% 
(59 - 78%) 
75% 
(66 - 84%) 
65% 
(55 - 75%) 
78% 
(69 - 86%) 
<5mm 
89% 
(83 - 96%) 
63% 
(53 - 72%) 
62% 
(52 -72%) 
90% 
(84 - 96%) 
<6mm 
95% 
(90 - 99%) 
43% 
(33 - 53%) 
53% 
(43 - 63%) 
92% 
(87 - 98%) 
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Table 3: Intra-observer variability of the inexperienced observer compared to the experienced 
research dietician. 
  
N = 69 
Inexperienced observer 
measurements 
Experienced research dietician 
measurements 
Mean SD CV (%) Mean SD CV (%) 
Waist circumference (cm) 0.49 0.48 97% 0.44 0.38 87% 
Hip circumference (cm) 0.33 0.27 82% 0.34 0.32 95% 
Mid-upper arm circumference (cm) 0.13 0.11 84% 0.13 0.10 78% 
Triceps SFT (mm) 0.42 0.33 79% 0.38 0.38 102% 
Biceps SFT (mm) 0.29 0.26 90% 0.24 0.26 106% 
Subscapular SFT (mm) 0.25 0.22 86% 0.17 0.16 92% 
Iliac crest SFT (mm) 0.41 0.30 74% 0.30 0.33 107% 
SFT=skin-fold thickness; CV=coefficient of variation; SD=standard deviation 
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Chapter 4 
Accuracy of the “opened capsule” dosing method for stavudine 
 
Abstract 
Introduction: Where a caregiver does not have access to a refrigerator, the South African National 
Department of Health has advised that stavudine adult capsule formulations be employed using the 
off-label “opened capsule” dosing method. The accuracy of this dosing method has not previously 
been validated.  
Aim: To assess the accuracy of the off-label “opened capsule” method for stavudine dosing in 
infants and children. In addition, we assessed the relative ease of dispersion of generic and original 
capsule preparations in water in order to determine which preparations, if any, are suitable for the 
off-label “opened capsule” dosing method.  
Method: We evaluated ten Zerit®, five Aspen Stavudine®, and five Cipla Stavir® capsules. Each 
capsule was dispersed in 30ml water, creating 20 separate solutions. Timed dispersion of each 
generic was compared to original (Zerit®). Each solution was then centrifuged to remove sediment, 
and the concentration of active drug (in mg/ml) was analysed using high-performance liquid 
chromatography.  
Results: The ease of dispersion of the contents of Aspen Stavudine® capsules was equivalent to that 
of Zerit®, and resulted in a mean recovery of active drug from solution of over 97%, confirming the 
accuracy of this dosing method.  The contents of Cipla Stavir® capsules, however, were extremely 
difficult to disperse in water despite prolonged agitation, and the recovery of active drug from 
solution was reduced as a result.   
Conclusion: The accuracy of the off-label “opened capsule” dosing method for stavudine is 
acceptable. There is no need to instruct caregivers to include sediment in the aliquot given to the 
infant. However, it is important to avoid supplying generic capsules whose contents do not disperse 
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easily in water, as this may lead to significant imprecision in the amount of active drug that a child 
receives.  
 
Aim 
The aim of this study was to assess the accuracy of the off-label “opened capsule” dosing method for 
stavudine dosing in infants and children. In addition, we assessed the relative ease of dispersion of 
generic and original capsule preparations in water in order to determine which preparations, if any, 
are suitable for the off-label “opened capsule” dosing method.  
 
Method  
In July 2008, we compared two of the commercially available generic adult stavudine capsules, 
Aspen Stavudine® and Cipla Stavir®, to the original preparation, Zerit® (Bristol-Myers-Squibb). We 
evaluated ten Zerit®, five Aspen Stavudine® capsules, and five Cipla Stavir® capsules. The generic 
capsules were obtained through the Western Cape Department of Health ARV depot. The Stavir® 
capsules were from lot X70669 expiry date 06/2009. The Zerit® capsules were purchased 
commercially by the Children's Infectious Diseases Clinical Research Unit (KID-CRU) pharmacy, 
Tygerberg Children’s Hospital. 
 
Each capsule was stated to contain 30mg of active drug, and was dispersed in 30ml water, thus 
creating 20 separate solutions. Rather than use the technical dispersion method for capsules 
described in the British Pharmacopoeia (95), we intentionally used the manual dispersion 
technique taught to caregivers in public sector clinics. However we used a larger volume of water 
than described in the National Department of Health guidelines (58), in order to avoid amplifying 
the effect of any inaccuracy from the manual technique, ensuring that the recovery of active drug 
from each solution could be fairly compared. All solutions were made up by the same investigator 
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using the same standardized method. Timed dispersion of each generic was compared to the 
original (Zerit®). Each solution was then centrifuged, and the concentration of active drug (in 
mg/ml) was analysed using high-performance liquid chromatography (HPLC).  
 
Statistical analysis was performed using JMP statistics software, version 7.0 (SAS Corporation – 
California). 
 
Laboratory method  
Undissolved particulate matter was separated from the solution by centrifugation and discarded. 
The stavudine containing samples were analyzed using an Hewlett Packard 1100 series high-
performance binary liquid chromatograph (Agilent Technologies, Waldbronn, Germany) with an 
Eclipse (XDB-C18) Zorbax analytical column (15 mm x 4.6 mm ID, 5µ particle size). The latter is 
preceded by a 30mm x 2.1 mm ID C 18 guard column (40 µ particle size).  The temperature was 
maintained at 40oC and the flow rate at 1 ml / min.  The mobile phase consisted of a mixture of two 
solvents, A (50 mM KH2PO4, pH 5.42) and B (acetonitrile: isopropanol, 4:1 (v/v)).  The following 
gradient was used: 0 – 1 minute = isocratic at 5 % B; 1 – 7.5 minutes = linear increase to 15% B, 7.5 
– 10 minutes isocratic at 15% B.  All reagents used for the mobile phase were HPLC grade (E. 
Merck, Darmstadt, Germany) and were filtered through a 0.45µ filter to remove particulate matter.  
Deionized water was used for the preparation of all aqueous solution and standards.  200µl of the 
sample was diluted with 800µl of deionized water to avoid detector overload and to ensure that 
detector response remained within linear range of the calibration curve. Aliquots of 5 µl from each 
sample were injected onto the column.  The variable wave detector was set at 266 nm.  The 
retention time of stavudine was 4.92 minutes with a total run time of 7.5 minutes.  A 3 minute post 
time was allowed for the column to stabilize at 5% B before each subsequent injection.  Recording 
and integration of the peaks were performed by means of an Agilent Chem Station.  Spiked 
Stellenbosch University http://scholar.sun.ac.za
72 
 
standards were prepared from pure stavudine compound (Aspen Laboratories, Batch # 13961 V), 
and were randomly included into each batch over the expected concentration range.  The 
calibration curve of triplicate samples was found to be linear over the entire concentration range, R2 
= 0.999915 (figure 1). The limits of quantification were 0.5 to 2mg/ml. 
 
Results 
All three capsule preparations produced a sediment that rapidly collected at the bottom of the 
container when the contents of a capsule were mixed into water (Figure 2).  
 
The contents of BMS Zerit® capsules dispersed easily with minimal agitation, resulting in a mean 
recovery of active drug from solution of over 97% (Table 1). The ease of dispersion of the contents of 
Aspen Stavudine® capsules was equivalent to that of Zerit®, resulting in a mean recovery of active 
drug from solution of over 97% (Table 1). The minor difference in recovery of active drug from 
solution when comparing Zerit® to Aspen Stavudine® was not statistically significant (p=0.8272), 
suggesting that these two drugs are likely to be equivalent when given to children using the off-label 
“opened capsule” administration method.   
  
The contents of Cipla Stavir® capsules were extremely difficult to disperse in water despite 
prolonged agitation. The contents of Cipla Stavir® capsules appeared to be partially hydrophobic, 
floating persistently on the meniscus of the sample. Recovery of active drug was reduced as a result 
(table 1).  However, due to the small sample size, the difference in recovery of active drug from 
solution when comparing Zerit® to Cipla Stavir® did not reach statistical significance (p=0.1730). 
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Discussion 
The lack of appropriate paediatric antiretroviral formulations is a global problem (96). The use of 
liquid formulations may not be feasible in resource-limited settings, since they are heavy and 
difficult to transport, have a short shelf-life, and may require refrigeration. Paediatric clinicians are 
often forced to use medicines in an off-label manner, as pharmaceutical companies tend to avoid 
the expense of developing paediatric formulations of established adult medicines unless the market 
demand is high. Although both the United States Federal Drug Administration and the European 
Medicines Agency now mandate that a paediatric plan be put in place for essential medicines, 
paediatric formulations are still often not appropriate. For this reason, where suitable solid 
paediatric antiretroviral formulations are not available, the World Health Organization (WHO) has 
recommended that off-label use of adult formulations should be investigated (97).   
 
When a drug is employed in an off-label manner in children, the clinical implications should be 
carefully considered. The dosing accuracy, bioavailability, efficacy and safety of using an adult 
formulation in children all require investigation. In addition, off-label use of adult formulations 
requires manipulation that may affect the dosage, such as either cutting adult tablets or emptying 
the contents of capsules into water and then giving a specific volume. These activities take time and 
may impact negatively on adherence. However, once tested, the off-label use of adult formulations 
in children can be extremely effective, as has become well established in fields such as paediatric 
cardiology (98).  
 
In our study, we found that when the contents of a stavudine capsule are dispersed in water, 
practically all the active drug is found in the supernatant, and, by inference, only a negligible 
amount remains in the visible sediment. It is likely that the sediment is composed only of the 
pharmacologically inactive excipients of the capsule formulation, such as magnesium stearate. This 
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information is important for caregivers, who do not need to re-suspend sediment when giving the 
solution to their infant. It is therefore unnecessary to instruct caregivers to agitate the mixture 
before withdrawing the aliquot to be given to the child. This important finding will help to simplify 
a technique that is at best difficult for elderly caregivers, who struggle with the dexterity and 
precision needed for this method.   
  
We found a significant difference in the ease of dispersion of the capsule contents of the two generic 
capsule preparations. This may lead to a significant reduction in the amount of active drug that a 
child receives when Cipla Stavir® capsules are supplied to caregivers. Further research into the 
effect of unskilled caregivers’ technique on dose preparation is needed. 
 
In the future, paediatric fixed drug combination (FDC) ARV formulations will greatly accelerate the 
roll-out of ARV’s to children in rural resource-limited settings. However, as yet no paediatric 
antiretroviral FDC’s have been registered in South Africa. Until FDC’s become widely available in 
the public sector, clinicians should use the best available data in prescribing adult ARV 
formulations in an off-label manner.  
 
The validity of these findings is limited by the following assumptions: 
1. The prescribed dose is correct: Where the dose is calculated per kilogram body weight, 
calculation errors may occur. Where weight-based dosing charts are used, a child with a weight 
at the lower end of the weight band may receive a far higher dose per kilogram body weight 
than a child with a weight at the upper end.  
2. The correct capsules are used: Generics available on-code change often and each have a 
different appearance. Poorly literate patients often depend on the colour of the capsule to 
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identify the medication. To add to the confusion, caregivers are often on similar-looking 
capsules themselves.   
3. Caregivers open the capsule successfully: Although the two halves of the proprietary capsule 
formulation separate easily, the halves of certain generic capsules are glued and thus very 
difficult to open without spilling. Precision with this technique requires dexterity, which 
elderly caregivers may not have. In addition, it is sometimes difficult to extract all the powder 
contents as some powder may remain in the tips of the capsule halves. 
4. Caregivers use the correct volume of water: Incorrect volumes may significantly alter the dose 
given to the child.  
5. The capsule’s powder contents disperse completely when mixed in water: Certain generic 
capsules contain excipients that are hydrophobic, causing the powder to float on the meniscus 
of the water and not disperse.  
 
Conclusion 
Although the method of dispersing the contents of a capsule in water is off-label, and not condoned 
by the manufacturers of any of the three preparations, our findings suggest that the accuracy of the 
off-label “opened capsule” dosing method for stavudine is acceptable. We have also shown that 
there is no need to instruct caregivers to include sediment in the aliquot given to the infant. 
However, it is important to use generic capsules whose contents disperse easily in water, as this may 
otherwise lead to significant imprecision in the amount of active drug that a child receives.  
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Figure 1: Calibration curve for pure stavudine compound.  The dotted line represents the best fit 
linear curve (y = 2678.121488 x – 6.446728, R2 = 0.999915) 
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Figure 2: The contents of stavudine capsules do not disperse completely, leaving a visible sediment 
at the bottom of the container. Z = Zerit®, A = Aspen Stavudine®, B = Cipla Stavir®. 
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Table 1: Comparison of the dispersibility and active drug content of mixtures made with original 
and generic brands of stavudine capsules using the “opened capsule” dosing method. 
 BMS Zerit® 
(N = 10) 
Aspen Stavudine® 
(N = 5) 
Cipla Stavir® 
(N = 5) 
Found concentration (mg/ml) 
Mean  
Standard deviation 
 
0.97136 
0.02181 
 
0.97391 
0.01862 
 
0.93767 
0.06961 
Ideal concentration (mg/ml) 1.00000 1.00000 1.00000 
Recovery (% of ideal)  
Mean  
Standard deviation 
 
97.136% 
2.181% 
 
97.391% 
1.862% 
 
93.767% 
6.961% 
Variation from ideal - 2.864% - 2.609% - 6.233% 
Time to total dissolution of the 
contents of a single capsule in 
water 
18 seconds 18 seconds >65 seconds 
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Chapter 5 
Bioavailability and pharmacokinetic profile of stavudine when given 
according to the “opened capsule” dosing method 
 Abstract  
Introduction: Stavudine, a nucleoside reverse transcriptase inhibitor, is used commonly to treat HIV-
infected children in the developing world. The paediatric liquid formulation presents major logistical 
difficulties in rural and resource-limited areas, and prescribers are frequently forced to employ off-
label “opened capsule” dosing methods using the adult capsule. South African Department of Health 
(DoH) has advised that caregivers should be instructed to disperse the contents of an adult capsule in 
5ml water and then withdraw the required dose using a syringe. The bioavailability of stavudine using 
the “opened capsule” dosing method has not previously been validated. 
Aim: to compare the bioavailability of stavudine administered as a solution using an “opened capsule” 
dosing method with the same dose given as an intact capsule in healthy adult volunteers. In addition, 
this study aimed to compare the bioequivalence of the two most commonly used generic stavudine 
capsule preparations available in South Africa. 
Method: This was a randomized crossover pharmacokinetic study with each subject serving as 
his/her own control. 28 healthy HIV-negative adult volunteers were randomized on a 1:1 basis to 
receive one of the two generic preparations. They were then further randomized to receive either 
intact or opened 30mg capsules. One week later, those who initially received intact capsules, were 
given opened capsules and vice versa. The capsule dispersion technique used was identical to that 
prescribed by DoH. Serial blood samples were collected and plasma stavudine concentrations were 
assayed by liquid chromatography tandem mass spectrometry. Stavudine pharmacokinetics were 
analyzed using non-compartmental analysis and formulations were compared using ANOVA.  
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Result: Plasma drug exposure after stavudine administration as a solution using an “opened capsule” 
dosing method was found to be bioequivalent to intact capsule administration. This was true for both 
generics tested. 
Conclusion: The “opened capsule” dosing technique is bioequivalent to intact capsule dosing for 
stavudine in HIV-seronegative adults.  
 
Aim    
This study aimed to compare the bioavailability of stavudine administered as a solution using an 
“opened capsule” dosing method with the same dose given as an intact capsule in healthy adult 
volunteers. In addition, this study aimed to compare the bioequivalence of the two most commonly 
used generic stavudine capsule preparations available in South Africa: Stavir® (Cipla Life Sciences, 
Mumbai, India) and Aspen Stavudine® (Aspen Pharma, Port Elizabeth, South Africa). 
 
Method 
Study Design 
This was a randomized crossover study with each subject serving as his/her own control.  After 
screening, 28 healthy HIV-negative adult volunteers were randomized on a 1:1 basis to receive one of 
the two generic preparations. They were then further randomized to receive either intact or opened 
30mg capsules. One week later, those who initially received intact capsules, were given opened 
capsules and vice versa (see table 1). Literature-based variability in exposure (AUC 2568 +/- 454 
ng*h/mL) for stavudine was accounted for in calculation of sample size for the study. A sample size of 
28 (14 per arm) would have a power of 0.99 to detect a 30% difference in AUC of formulations, or a 
power of 0.85 to detect a 20%, at an alpha value of 0.05. 
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This study received approval from the ethics committee of Stellenbosch University and was 
conducted in accordance with the Declaration of Helsinki.  
 
Study procedures  
Participants were fasted from six hours prior until two hours after the dose was given. The dispersion 
technique used was identical to that prescribed by the DoH (58): Each capsule was opened by the 
pharmacist and mixed into 5ml water, and agitated until completely dispersed. The mixture was 
immediately swallowed by the participant, under direct supervision. Stavudine pharmacokinetic 
blood samples were collected at the following times:  Predose, 15 minutes, 30 minutes, 45 minutes, 
60 minutes, 90 minutes, 2 hours, 4 hours, 6 hours and 8 hours after dosing. The reason for only 
sampling to 8 hours relates to the very short half-life of Stavudine (~1hr).  With absorption nearly 
complete by 1 hour, less than 1% of peak plasma drug level is present in the bloodstream after 8 
hours. Samples were processed on-site and frozen within 8 hours of collection. Samples remained 
frozen at -70oC until analysis. 
 
Assay Method 
Plasma stavudine concentrations were assayed by liquid chromatography tandem mass spectrometry 
using a validated method on an API 4000 LC mass spectrometer.  The mobile phase consisted of 
gradient of acetonitrile and 0.5% glacial acetic acid. Chromatography was performed on a 
Phenomonex Synergi fusion C18 column maintained at 25°C.  2-deoxythymidine was used as an 
internal standard.  For each participant, all pharmacokinetic samples were processed in a single 
batch. 50µL of each sample was precipitated with acetonitrile containing the internal standard, 
centrifuged and 5µL of the supernatant injected onto the column.  Standard curves in the range 0.02 
– 6µg/mL and appropriate quality control samples were run with each batch.   The lower limit of 
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quantification was 20ng/mL.  Inter- and intra-day coefficients of variation were below 9% for all 
quality control samples. 
 
Data Analysis 
The Food and Drug Administration (FDA) considers two products bioequivalent if the 90% 
confidence interval of the log transformed Cmax and AUC of the test formulation in the fasting state is 
between 80% and 125% of the reference formulation (99). A formal pharmacokinetic (PK) study is the 
ideal for determining this. However, the large number of blood draws required for a formal PK study, 
are impractical in small children. Healthy adult volunteers are an acceptable surrogate for 
bioequivalence studies of generic medicines, including antiretrovirals (100-102). This principle 
spares children much unnecessary pain, and is supported by the FDA (99, 103). 
 
The PK analysis was performed using noncompartmental methods and ANOVA bioequivalence 
analysis using WinNonlin version 5.3.  This included a 90% confidence interval of the ratio of log 
transformed parameters (Cmax and AUC0-infinity), as per FDA guidance on bioequivalence studies (99). 
AUC0-infinity was calculated using the linear/log trapezoidal rule. The maximum observed 
concentration was taken as Cmax. If that concentration was not unique, then the first observed value 
was used in the AUC determination. 
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Results 
This study was planned and performed between April 2008 and March 2010. Baseline characteristics 
of participants were well matched with an overall median age of 37.5 (range 22-61) years (see table 2).  
Plasma drug exposure after stavudine administration as a solution using an “opened capsule” dosing 
method was bioequivalent to intact capsule administration. This was true for both generics tested, i.e. 
Aspen Stavudine® and Cipla Stavir® (table 3). The median ratio of   AUC0-8 to AUC0-infinity was 0.947, 
confirming that sampling time was sufficiently long, and that AUC0-8 is a reasonable estimation of 
AUC0-infinity. 
 
For Aspen Stavudine®, there was no statistically significant difference in the PK parameters (Tmax, 
Cmax and AUC) or the mean concentration-time profiles of the “opened capsule” versus intact capsule 
dosing methods (see figure 1 and table 4). For Cipla Stavir®, the Tmax after intact capsule dosing was 
significantly later than after “opened capsule” dosing (0.87hr vs 0.53hr; p=0.0078) (see table 5). This 
difference is clearly visible in the superimposed mean concentration-time profiles of the two dosing 
methods (see figure 2).  
 
Discussion 
Our data shows that administration of stavudine as a solution using an “opened capsule” dosing 
method is bioequivalent to intact capsule dosing. This was true for both generics tested (Aspen 
Stavudine® and Cipla Stavir®). Although still within the prescribed PK parameters, Cipla Stavir® 
capsules, when dispersed in water, follow a different PK curve to that of intact Cipla Stavir® capsules. 
Therefore Cipla Stavir® may not be an ideal product when an “opened capsule” dosing method is 
prescribed. This finding is in line with our previous study of the physical characteristics of generic 
stavudine capsules, which found a significant delay in the dispersability of Cipla Stavir®  capsule 
contents compared Bristol Myer Squibb Zerit® capsules and to Aspen Stavudine® capsules. Although 
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the “opened capsule” dosing method has been prescribed by the South African Department of Health 
since 2004, none of the three stavudine capsule patient information leaflets condone the use of an 
“opened capsule” dosing technique (56-57, 104), and it remains an off-label dosing method. 
 
The cumulative amount of stavudine that children are exposed to needs review. The standard 
stavudine dose for children (1mg/kg twice daily) may need to be re-evaluated in the light of the 2007 
reduction in the adult dose (50) following accumulation of evidence that a dose as low as half the 
previous standard dose results in a significantly lower frequency of delayed toxicity (lipoatrophy, 
lacticacidosis, peripheral neuropathy) while maintaining excellent antiviral efficacy (42). Stavudine is 
rapidly cleared from circulation after dosing (t1/2 = ~1 hour) (51), and the magnitude of its antiviral 
and toxic effect depends on the intracellular concentration of its phosphorylated metabolite, 
stavudine-triphosphate (t1/2 = ~7 hours), rather than on the concentration of free drug in plasma 
(105). Studies are needed to compare the intracellular concentration of stavudine-triphosphate in 
children on 0.5mg/kg/dose twice daily to that of adults on 20mg twice daily in order to recommend a 
reduction in the paediatric dose of stavudine.  
 
The validity of our findings is limited by the following assumptions: 
1. The correct capsules are used: Generics available on-code change often and each have a 
different appearance. Poorly literate patients often depend on the colour of the capsule to 
identify the medication. To add to the confusion, caregivers are often on similar-looking 
capsules themselves.   
2. The capsules have been correctly stored and are not out-of-date.   
3. Caregivers open the capsule successfully: Although the two halves of the proprietary capsule 
formulation separate easily, the halves of certain generic capsules are glued and thus very 
difficult to open without spilling. Precision with this technique requires dexterity, which 
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elderly caregivers may not have. In addition, it is sometimes difficult to extract all the powder 
contents as some powder may remain in the tips of the capsule halves. 
4. Caregivers use the correct volume of water: Incorrect volumes may significantly alter the dose 
given to the child.  
5. The capsule’s powder contents disperse completely when mixed in water: Certain generic 
capsules contain excipients that are hydrophobic, causing the powder to float on the meniscus 
of the water and not disperse.  
6. The volume of mixture extracted by the caregiver and fed to the child is correct and that the 
child swallows it all without spilling. 
 
 
Conclusion  
The off-label “opened capsule” dosing method is bioequivalent to intact capsule dosing for stavudine. 
A suitable product should be supplied when this method is prescribed.  
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Figure 1: Mean plasma concentration-time profiles after opened and intact capsule dosing for Aspen 
Stavudine®. Error bars reflect the standard error of the mean.  
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Figure 2: Mean plasma concentration-time profiles after opened and intact capsule dosing for Cipla 
Stavir®. Error bars reflect the standard error of the mean.  
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Table 1: Outline of study design 
 Study visit 1 Study visit 2 
Cohort 1: 
Aspen Stavudine® 
(n=14) 
Intact capsules  
(n=7) 
Opened capsules mixed with water  
(n=7) 
Opened capsules mixed with water 
(n=7) 
Intact capsules  
(n=7) 
Cohort 2: 
Cipla Stavir® 
 (n=14) 
Intact capsules  
(n=7) 
Opened capsules mixed with water  
(n=7) 
Opened capsules mixed with water 
(n=7) 
Intact capsules  
(n=7) 
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Table 2: Baseline characteristics of participants  
 Participants randomized to 
receive Aspen Stavudine® 
Participants randomized to 
receive Cipla Stavir® 
Gender distribution 3 male / 11 female 6 male / 8 female 
Median age 
  (range) 
35 years 
(22 – 54 years) 
40 years 
(21 – 61 years) 
Mean weight 
  (range) 
74 kg 
(50 – 117 kg) 
82 kg 
(56 – 138 kg) 
Mean body surface area 
  (range) 
1.85 m2 
(1.51 – 2.52 m2) 
1.92 m2 
(1.62 – 2.45 m2) 
Mean serum creatinine 
concentration 
  (range) 
 
83 µmol/L 
(60 – 114 µmol/L) 
 
84 µmol/L 
(61 – 106 µmol/L) 
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Table 3: Bioequivalence of stavudine administered as a solution using an “opened capsule” dosing 
method, compared to the same dose given as an intact capsule.  
 Opened capsule 
Mean (SD) 
Reference formulation 
(Intact capsule) 
Mean (SD) 
Geometric least 
squares mean ratio 
(90% confidence interval) 
Cmax (ng/ml) 
    Aspen Stavudine®     
    Cipla Stavir® 
 
739  (256) 
782  (229) 
 
787  (255) 
706  (138) 
 
105%  (90 – 123%)  
103%  (88 – 121%) 
AUC0-infinity 
(ng.h/ml) 
    Aspen Stavudine®     
    Cipla Stavir® 
 
 
1601  (534) 
1540  (226) 
 
 
1787  (467) 
1768  (369) 
 
 
112%  (102 – 122%)  
94%  (90 – 99%) 
 
Stellenbosch University http://scholar.sun.ac.za
91 
 
 
Table 4: Aspen Stavudine® bioavailability data for each participant: Calculated pharmacokinetic parameters Tmax, Cmax, Half life, 
AUC0-8 and AUC0-infinity  
Participant 
No. 
Tmax (h) Cmax (ng/ml) Half Life (h) AUC0-8 (ng.h/ml) AUC0-infinity. (ng.h/ml) 
Intact Open Intact Open Intact Open Intact Open Intact Open 
1 0.5 0.5 1140 752 2.3597 2.2757 1727.31 1522.45 1870.29 1695.14 
2 0.75 0.75 695 561 2.2123 2.8631 2330.84 2130.44 2590.95 2485.67 
3 0.25 0.25 1030 975 1.4967 1.6909 1496.45 2296.14 1553.46 2367.61 
4 0.75 0.75 868 723 1.9823 2.3035 2128.64 1711.16 2305.09 1861.37 
5 1.5 0.25 470 880 1.2191 1.2025 1080.46 1213.2 1148.18 1250.15 
6 1 0.25 628 771 1.6009 1.901 1799.55 1591.68 1870.22 1791.33 
7 0.75 0.5 480 451 2.3961 1.8854 925.9 953.05 1084.57 1027.58 
8 1 0.5 603 605 1.5563 1.5426 1446.63 872.98 1501.63 1027.87 
9 0.5 1 861 511 1.3662 1.6372 1912.4 1681.53 1953.20 1759.47 
10 0.5 0.5 487 454 1.7086 1.36 1205.8 942.88 1316.23 987.61 
11 0.5 0.25 987 1370 1.4085 1.2662 1940.05 1843.1 2074.58 1921.83 
12 0.5 0.75 1090 651 1.1533 1.2269 1586.65 1209.25 1635.57 1259.34 
13 2 1 555 611 - 0.4302 1175.35 778.88 - 854.60 
14 0.5 0.5 1120 1030 1.2386 1.195 2268 2063.23 2332.33 2117.70 
Mean 0.7857 0.5536 786.7 738.9 1.669 1.627 1645 1486 1787 1601 
SD 0.4688 0.2627 254.9 255.7 0.4341 0.6026 446.8 499.2 467.1 534.1 
SEM 0.1253 0.07022 68.12 68.33 0.1204 0.1610 119.4 133.4 129.6 142.7 
%CV 59.67% 47.46% 32.40% 34.60% 26.00% 37.03% 27.17% 33.58% 26.13% 33.37% 
* Parametric t test, ** Non-parametric t test both using matched pairs 
SEM = standard error of the mean. %CV = coefficient of variation given as a percentage.
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Table 5: Cipla Stavir® bioavailability data for each participant: Calculated pharmacokinetic parameters Tmax, Cmax, Half life,  
AUC0-8 and AUC0-infinity  
Participant 
No. 
Tmax (h) Cmax (ng/ml) Half Life (h) AUC0-8 (ng.h/ml) AUC0-infinity. (ng.h/ml) 
Intact Open Intact Open Intact Open Intact Open Intact Open 
15 0.5 0.5 875 991 1.8462 1.6303 2111.28 1635.10 2354.71 1762.34 
16 1 0.75 606 1180 1.1995 1.1467 1499.65 1203.93 1548.80 1315.26 
17 0.5 0.5 869 956 1.4444 0.8693 1651.00 1347.45 1718.52 1411.04 
18 0.5 0.5 812 458 1.4966 1.685 1320.40 1203.38 1409.36 1322.49 
19 1 0.25 691 1040 1.5719 1.0925 2106.53 1461.53 2190.66 1500.14 
20 1.5 0.5 866 744 1.5652 1.7695 2015.11 1762.68 2112.21 1852.02 
21 0.5 0.5 750 928 1.9687 1.4127 1668.65 1569.38 1775.44 1649.88 
22 0.75 0.75 874 970 1.6107 1.5522 2300.29 1929.85 2410.20 2033.09 
23 1.5 0.5 477 588 1.7236 1.7001 1629.73 1555.98 1707.81 1623.67 
24 0.5 0.5 730 438 2.4669 2.0183 1578.85 1367.15 1736.16 1446.35 
25 1.5 0.75 569 687 2.3251 1.3949 1529.43 1454.33 1646.50 1535.23 
26 1 0.5 553 681 1.2265 1.184 1159.40 1160.40 1205.76 1217.11 
27 1 0.75 592 592 2.2249 2.0095 1437.70 1288.40 1549.40 1378.56 
28 0.5 0.25 620 701 2.5834 2.6506 1247.03 1366.09 1380.83 1517.90 
Mean 0.8750 0.5357 706.0 782.4 1.804 1.580 1661 1450 1768 1540 
SD 0.4013 0.1657 138.1 228.7 0.4474 0.4588 348.1 222.5 368.6 226.1 
SEM 0.1073 0.04430 36.91 61.12 0.1196 0.1226 93.04 59.47 98.51 60.43 
%CV 45.87% 30.94% 19.56% 29.23% 24.80% 29.05% 20.96% 15.34% 20.85% 14.68% 
* Parametric t test, ** Non-parametric t test both using matched pairs 
SEM = standard error of the mean. %CV = coefficient of variation given as a percentage. 
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Summary of conclusions 
Lipoatrophy is a common adverse effect of stavudine and this effect is strongly dose-dependent. 
Although lipoatrophy was previously believed to be uncommon in children, the current study found 
that the prevalence of visually obvious lipoatrophy in pre-pubertal children on antiretroviral therapy 
in South Africa is around 36%, and the incidence is around 12% per person-year. The risk of 
lipoatrophy increases progressively as time on standard-dose stavudine accumulates.  
 
Biceps skin-fold thickness may provide reasonable sensitivity and specificity as a simple screening 
tool to detect and predict lipoatrophy at an early stage. This may be a relatively objective, easy-to-use 
surveillance method to screen for lipoatrophy at primary healthcare level in resource-constrained 
settings where trained specialists are scarce and complex special investigations are not available. This 
will assist earlier antiretroviral drug switches to be made to arrest progression of lipoatrophy and 
prevent potentially stigmatizing face and limb disfigurement. A follow-up study is needed to test the 
performance of this screening tool on a different group of pre-pubertal HIV-infected South African 
children on ART.  
 
The off-label dosing method for stavudine prescribed for children whose caregiver does not have 
access to a refrigerator is reasonably accurate. However, it is important to avoid supplying generic 
capsules whose contents do not disperse easily in water, as this may lead to significant imprecision in 
the amount of active drug that a child receives. In addition, the method requires dexterity and careful 
measuring, which may be challenging for elderly caregivers. The bioavailability of this dosing method 
is similar to intact capsule dosing for stavudine in HIV-seronegative adults. These findings pave the 
way for future studies to investigate a possible reduction of the recommended paediatric dose.  
Stellenbosch University http://scholar.sun.ac.za
94 
 
References  
1. Dieffenbach C. Looking Ahead: NIAID’s Future HIV/AIDS Therapeutics Priorities. 2010 
[updated 2010; cited 20 August 2012]; Available from: http://blog.aids.gov/2010/06/looking-ahead-niaids-
future-hivaids-therapeutics-priorities.html. 
2. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. 
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-
sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-18. PMCID: 2739977. 
3. Innes S, Levin L, Cotton MF. Lipodystrophy syndrome in HIV-infected children on HAART. 
SAJ HIV Med. 2009;10(4):76-80. PMCID: 2919754. 
4. Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A, Thorne C. Body fat 
abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors 
Fat abnormality in children. J Acquir Immune Defic Syndr. 2011. 
5. Eley B. Metabolic complications of antiretroviral therapy in HIV-infected children. Expert 
Opin Drug Metab Toxicol. 2008;4(1):37-49. 
6. WHO, UNAIDS, and UNICEF. Global HIV/AIDS Response: Epidemic update and health 
sector progress towards universal access, Progress Report 2011. 2011 [updated 2011; cited 2012 5 
September ]; Available from: 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_epi_core_en.pdf. 
7. Shiau S, Arpadi S, Strehlau R, Martens L, Coovadia A, Abrams E, et al. Body composition and 
metabolic abnormalities of perinatally HIV-infected children in South Africa on long-term ARV 
treatment.  3rd International workshop on HIV paediatrics; 15-16 July 2011; Rome 2011. 
8. Reynolds NR, Neidig JL, Wu AW, Gifford AL, Holmes WC. Balancing disfigurement and fear 
of disease progression: Patient perceptions of HIV body fat redistribution. AIDS Care. 
2006;18(7):663-73. 
Stellenbosch University http://scholar.sun.ac.za
95 
 
9. Greeff M, Phetlhu R, Makoae L, Dlamini P, Holzemer W, Naidoo J, et al. Disclosure of HIV 
status: experiences and perceptions of persons living with HIV/AIDS and nurses involved in their 
care in Africa. Qualitative Health Research. 2008;18(3):311-24. 
10. Nyblade L, Pande R, Mathur S, MacQuarrie K, Kidd R, Banteyerga H, et al. Disentangling HIV 
and AIDS stigma in Ethiopia, Tanzania and Zambia. Washington DC: International Center for 
Research on Women; 2003. 
11. Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, et al. Failure to maintain long-term 
adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15(18):2441-
4. 
12. Aurpibul L, Puthanakit T, Taejaroenkul S, Sirisanthana T, Sirisanthana V. Recovery from 
lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-
nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J. 
2012;31(4):384-8. 
13. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al. Abacavir substitution for 
nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002;288(2):207-15. 
14. Vigano A, Brambilla P, Cafarelli L, Giacomet V, Borgonovo S, Zamproni I, et al. Normalization 
of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from 
protease inhibitor to efavirenz. Antivir Ther. 2007;12(3):297-302. 
15. Stankov MV, Lucke T, Das AM, Schmidt RE, Behrens GM. Mitochondrial DNA depletion and 
respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside 
analogue reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 2010;54(1):280-
7. 
16. Statistics South Africa. Mid-year population estimates 2009 [updated 2009; cited July 2010]; 
Available from: http://www.statssa.gov.za/publications/P0302/P03022009.pdf. 
Stellenbosch University http://scholar.sun.ac.za
96 
 
17. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggini V, Lepri AC, et al. Genetic polymorphisms 
differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. 
AIDS (London, England). 2008;22(14):1769-78. 
18. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, et al. Longitudinal 
evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected 
children. J Acquir Immune Defic Syndr. 2005;40(2):161-8. 
19. Dzwonek AB, Lawson MS, Cole TJ, Novelli V. Body fat changes and lipodystrophy in HIV-
infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 
2006;43(1):121-3. 
20. Ene L, Goetghebuer T, Hainaut M, Peltier A, Toppet V, Levy J. Prevalence of lipodystrophy in 
HIV-infected children: a cross-sectional study. Eur J Pediatr. 2007;166(1):13-21. 
21. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and 
hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18(10):1443-51. 
22. Jackson-Leach R, Lobstein T. Estimated burden of paediatric obesity and co-morbidities in 
Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J 
Pediatr Obes. 2006;1(1):26-32. 
23. Renaud-Thery F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, Habiyambere V, et al. 
Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income 
countries. AIDS research and treatment. 2011(Journal Article):749041. 
24. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, et al. Evidence of 
nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of 
mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 
2002;29(2):117-21. 
Stellenbosch University http://scholar.sun.ac.za
97 
 
25. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Changes in 
mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 
2002;346(11):811-20. 
26. Dragovic G, Jevtovic D. Nucleoside reverse transcriptase inhibitor usage and the incidence of 
peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother. 2003;14(5):281-4. 
27. Hurst M, Noble S. Stavudine: an update of its use in the treatment of HIV infection. Drugs. 
1999;58(5):919-49. 
28. Fielder J, Rambiki K. Occurrence of stavudine-induced lactic acidosis in 3 members of an 
African family. J Int Assoc Physicians AIDS Care (Chic). 2010;9(4):236-9. 
29. Tukei VJ, Asiimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, et al. Safety and 
tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J 
Acquir Immune Defic Syndr. 2012;59(3):274-80. 
30. Montaner JS, Cote HC, Harris M, Hogg RS, Yip B, Chan JW, et al. Mitochondrial toxicity in the 
era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected 
patients taking antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;34 Suppl 1:S85-90. 
31. Petit C, Mathez D, Barthelemy C, Leste-Lasserre T, Naviaux RK, Sonigo P, et al. Quantitation 
of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced 
mitochondrial DNA depletion. J Acquir Immune Defic Syndr. 2003;33(4):461-9. 
32. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, et al. Assessment of 
growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin 
Endocrinol Metab. 2001;86(2):504-10. 
33. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. 
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse 
transcriptase inhibitor-based antiretroviral therapy. Antivir Ther. 2007;12(8):1247-54. 
Stellenbosch University http://scholar.sun.ac.za
98 
 
34. Asensi V, Rego C, Montes AH, Collazos J, Carton JA, Castro MG, et al. IL-1beta (+3954C/T) 
polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active 
antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet Med. 2008;10(3):215-23. 
35. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, Kiertiburanakul S, 
Charoenyingwattana A, Komindr S, et al. Association between HLA-B*4001 and lipodystrophy 
among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral 
regimen. Clin Infect Dis. 2010;50(4):597-604. 
36. Hendrickson SL, Kingsley LA, Ruiz-Pesini E, Poole JC, Jacobson LP, Palella FJ, et al. 
Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy. J 
Acquir Immune Defic Syndr. 2009;51(2):111-6. PMCID: 2742970. 
37. Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jarvinen H, et al. Assessment of 
adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and 
zidovudine-containing regimens. J Acquir Immune Defic Syndr. 2005;40(5):565-72. 
38. Mallewa JE, Wilkins E, Vilar J, Mallewa M, Doran D, Back D, et al. HIV-associated 
lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother. 
2008;62(4):648-60. 
39. McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS. 
2004;18(13):1753-68. 
40. Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT. Antiretroviral therapy-associated 
toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis. 2007;196 
Suppl 3:S449-56. 
41. ter Hofstede HJ, Koopmans PP, Burger DM. Stavudine plasma concentrations and 
lipoatrophy. J Antimicrob Chemother. 2008;61(4):933-8. 
Stellenbosch University http://scholar.sun.ac.za
99 
 
42. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review 
of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin 
Pharmacother. 2007;8(5):679-88. 
43. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, et al. A randomized 
comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons 
with lipoatrophy. AIDS. 2006;20(16):2043-50. 
44. Caso JA, Prieto Jde M, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in 
HIV-infected men treated with efavirenz. AIDS. 2001;15(11):1447-8. 
45. Mercie P, Viallard JF, Thiebaut R, Faure I, Rispal P, Leng B, et al. Efavirenz-associated breast 
hypertrophy in HIV-infection patients. AIDS. 2001;15(1):126-9. 
46. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose 
tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease 
inhibitors. AIDS. 1999;13(10):F63-70. 
47. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, et al. 
Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and 
lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther. 2009;14(2):241-8. 
48. McComsey GA, Lo Re V, 3rd, O'Riordan M, Walker UA, Lebrecht D, Baron E, et al. Effect of 
reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial 
toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis. 2008;46(8):1290-6. 
PMCID: 2430521. 
49. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barreiro P, Gonzalez-Lahoz J, Soriano V. 
Reductions in stavudine dose might ameliorate mitochondrial-associated complications without 
compromising antiviral activity. HIV Clin Trials. 2005;6(4):197-202. 
Stellenbosch University http://scholar.sun.ac.za
100 
 
50. WHO. Addendum to 2006 WHO guidelines on antiretroviral therapy for HIV infection in 
adults and adolescents. WHO 2007 [updated 2007; cited 2008 26 August ]; Available from: 
http://www.who.int/hiv/art/ARTadultsaddendum.pdf. 
51. Dudley MN, Graham KK, Kaul S, Geletko S, Dunkle L, Browne M, et al. Pharmacokinetics of 
stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992;166(3):480-5. 
52. Kaul S, Kline MW, Church JA, Dunkle LM. Determination of dosing guidelines for stavudine 
(2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection. 
Antimicrob Agents Chemother. 2001;45(3):758-63. PMCID: 90369. 
53. Kline MW, Dunkle LM, Church JA, Goldsmith JC, Harris AT, Federici ME, et al. A phase I/II 
evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 
1995;96(Journal Article):247-52. 
54. WHO. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal 
Access. 2010 [updated 2010; cited 22 August 2012]; Available from: 
http://whqlibdoc.who.int/publications/2010/9789241599801_eng.pdf. 
55. WHO. Forecasting antiretroviral demand. 2010 [updated 2010; cited 15 September 2011]; 
Available from: http://www.who.int/hiv/amds/forecasting/en/index4.html. 
56. Bristol-Myers Squibb. ZERIT® (stavudine) Patient Information Leaflet 2007. 
57. Aspen Pharmacare. Aspen Stavudine® Patient Information Leaflet 
2006. 
58. South African National Department of Health Paediatric Consensus team, Meyers T, Eley B, 
Loening W. Khomanani Guidelines for the management of HIV-infected children (1st edition) 
Pinetown South Africa: Jacana Publishers; 2005. 
59. South African National Department of Health. Guidelines for the Management of HIV in 
Children (2nd edition). Pinetown South Africa: Jacana Publishers; 2010. 
Stellenbosch University http://scholar.sun.ac.za
101 
 
60. Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C. Long-term subcutaneous tissue changes 
among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine. J 
Acquir Immune Defic Syndr. 2008;48(1):53-62. 
61. Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, McKinney RE, Jr., et al. A 
randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with 
human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team. Pediatrics. 
1998;101(2):214-20. 
62. Southern African HIV Clinicians Society. Antiretroviral Pricelist. 2010 [updated 2010; cited 
2011 1 September]; Available from: http://www.sahivsoc.org/indexARV.php/arvpricelist. 
63. Buck WC, Kabue MM, Kazembe PN, Kline MW. Discontinuation of standard first-line 
antiretroviral therapy in a cohort of 1434 Malawian children. J Int AIDS Soc. 2010;13:31. PMCID: 
2923102. 
64. Esteban PM, Thahn TG, Bravo JF, Roca LK, Quispe NM, Montano SM, et al. Malnutrition 
associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J 
Acquir Immune Defic Syndr. 2009;52(5):656-8. 
65. Govender R, Eley B, Walker K, Petersen R, Wilmshurst JM. Neurologic and neurobehavioral 
sequelae in children with human immunodeficiency virus (HIV-1) infection. J Child Neurol. 
2011;26(11):1355-64. 
66. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of 
lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361(9359):726-35. 
67. Podzamczer D, Ferrer E, Martinez E, Del Rio L, Rosales J, Curto J, et al. How much fat loss is 
needed for lipoatrophy to become clinically evident? AIDS Res Hum Retroviruses. 2009;25(6):563-7. 
68. Hartman K, Verweel G, de Groot R, Hartwig NG. Detection of lipoatrophy in human 
immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy. Pediatr 
Infect Dis J. 2006;25(5):427-31. 
Stellenbosch University http://scholar.sun.ac.za
102 
 
69. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of 
lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children 
receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. 
Pediatrics. 2004;114(2):e235-42. 
70. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil 
fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact 
on bone mineral density in HIV-infected children. Pediatrics. 2006;118(3):e711-8. 
71. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with 
off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J 
Pediatr. 2008;152(4):582-4. PMCID: 2390888. 
72. Soler-Palacin P, Melendo S, Noguera-Julian A, Fortuny C, Navarro ML, Mellado MJ, et al. 
Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing 
HAART regimens. AIDS. 2011;25(2):171-6. 
73. Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H, et al. Tenofovir use in human 
immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 
2009;28(3):204-9. 
74. Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, et al. A randomized 
comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil 
fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic 
Syndr. 2009;51(5):562-8. 
75. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, et al. 
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human 
immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the 
results of the TARHEEL study. Clin Infect Dis. 2004;38(2):263-70. 
Stellenbosch University http://scholar.sun.ac.za
103 
 
76. Carey DL, Baker D, Rogers GD, Petoumenos K, Chuah J, Easey N, et al. A randomized, 
multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. J Acquir Immune 
Defic Syndr. 2007;46(5):581-9. 
77. McComsey GA, O'Riordan M, Setzer B, Lebrecht D, Baron E, Walker UA. Uridine 
supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J 
Clin Nutr. 2008;62(8):1031-7. 
78. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth 
hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. 
79. Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, et al. Effect of HIV 
infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to 
pneumococcal conjugate vaccine in infants. J Infect Dis. 2010;202(3):355-61. PMCID: 2902789. 
80. IeDEA Southern Africa Paediatric Group. A biregional survey and review of first-line treatment 
failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. J Int 
AIDS Soc. 2011;14:7. PMCID: 3058075. 
81. South African National Department of Health. The South African Antiretroviral Treatment 
Guidelines. Pretoria2010. 
82. Innes S, Eagar R, Edson C, Rabie H, Hough S, Haubrich R, et al. Prevalence, DEXA differences 
and risk factors for lipoatrophy among pre-pubertal African children on HAART. Reviews in Antiviral 
Therapy and Infectious Diseases 2011(8):36. 
83. Peretti-Watel P, Spire B, Pierret J, Lert F, Obadia Y. Management of HIV-related stigma and 
adherence to HAART: evidence from a large representative sample of outpatients attending French 
hospitals (ANRS-EN12-VESPA 2003). AIDS Care. 2006;18(3):254-61. 
84. Plankey M, Bacchetti P, Jin C, Grimes B, Hyman C, Cohen M, et al. Self-perception of body fat 
changes and HAART adherence in the Women's Interagency HIV Study. AIDS Behav. 2009;13(1):53-
9. PMCID: 2902995. 
Stellenbosch University http://scholar.sun.ac.za
104 
 
85. DeLaMora P, Aledort N, Stavola J. Caring for adolescents with HIV. Curr HIV/AIDS Rep. 
2006;3(2):74-8. 
86. Innes S, Eagar R, Edson C, Rabie H, Hough S, Haubrich R, et al. High prevalence of 
lipoatrophy in pre-pubertal South African children on antiretroviral therapy: A cross-sectional study 
BMC Pediatrics. 2012;12(1):183. 
87. UNAIDS. Report on the Global AIDS Epidemic. 2010 [updated 2010; cited 8 September 2011]; 
Available from: http://www.unaids.org/globalreport/global_report.htm  
88. South African National Department of Health. Operational Plan for Comprehensive HIV and 
AIDS Care, Management and Treatment for South Africa. 2003. 
89. Baty International. Harpenden skin-fold caliper West Sussex, United Kingdom; 2007 [updated 
2007; cited 2012 30 August]; Available from: http://www.harpenden-skinfold.com. 
90. McClish DK. Analyzing a portion of the ROC curve. Med Decis Making. 1989;9(3):190-5. 
91. Schmidt PK, Carter JE. Static and dynamic differences among five types of skinfold calipers. 
Hum Biol. 1990;62(3):369-88. 
92. Berberoglu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis 
and current management. J Clin Res Pediatr Endocrinol. 2009;1(4):164-74. PMCID: 3005651. 
93. Youlton R, Valladares L, Garcia H, Cattani A, Jara A, Iijmes J, et al. Premature telarche: Study 
of its frequency and etiological factors. Pediatric Research. 1990;28:421. 
94. Gerver WJ, de Bruin R. Body composition in children based on anthropometric data. A 
presentation of normal values. Eur J Pediatr. 1996;155(10):870-6. 
95. British Pharmacopoeia Commission. British Pharmacopoeia  London: TSO (The Stationery 
Office); 2008. 
96. Lallemant M, Chang S, Cohen R, Pecoul B. Pediatric HIV--a neglected disease? N Engl J Med. 
2011;365(7):581-3. 
Stellenbosch University http://scholar.sun.ac.za
105 
 
97. WHO. Make Medicines Child-size. 2010 [updated 2010; cited 2012 5 September]; Available 
from: http://www.who.int/mediacentre/factsheets/fs341/en/index.html. 
98. Pasquali SK, Hall M, Slonim AD, Jenkins KJ, Marino BS, Cohen MS, et al. Off-label use of 
cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ 
Cardiovasc Qual Outcomes. 2008;1(2):74-83. 
99. U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivalence 
Studies for Orally Administered Drug Products. 2003. 
100. Abdel-Rahman SM, Johnson FK, Gauthier-Dubois G, Weston IE, Kearns GL. The 
bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral 
liquid formulations compared with capsule. J Clin Pharmacol. 2003;43(2):148-53. 
101. Lewis L, on behalf of U.S. Food and Drug Administration. Development of Pediatric ARV 
Drugs – FDA Perspective. 2005 [updated 2005; cited 2010 14 June]; Available from: 
http://www.who.int/3by5/en/19lewis.ppt. 
102. Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a 
pediatric amlodipine suspension. Pediatr Nephrol. 2003;18(7):675-8. 
103. U.S. Food and Drug Administration. Guidance for Industry: Fixed Dose Combinations, Co-
Packaged Drug Products, and Single-EntityVersions of Previously Approved Antiretrovirals for the 
Treatment of HIV. 2006. 
104. Cipla Life Sciences. Stavir® (stavudine) Patient Information Leaflet. . Mumbai, India2003. 
105. Domingo P, Cabeza MC, Pruvost A, Salazar J, Gutierrez Mdel M, Mateo MG, et al. Relationship 
between HIV/Highly Active Antiretroviral Therapy (HAART)-Associated Lipodystrophy Syndrome 
and Stavudine-Triphosphate Intracellular Levels in Patients with Stavudine-Based Antiretroviral 
Regimens. Clin Infect Dis. 2010;50(7):1033-40. 
 
 
Stellenbosch University http://scholar.sun.ac.za
